ug20210630_10q.htm

0001171843-21-005820.txt : 20210811 0001171843-21-005820.hdr.sgml : 20210811 20210811125832 ACCESSION NUMBER: 0001171843-21-005820 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210811 DATE AS OF CHANGE: 20210811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED GUARDIAN INC CENTRAL INDEX KEY: 0000101295 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 111719724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10526 FILM NUMBER: 211162770 BUSINESS ADDRESS: STREET 1: 230 MARCUS BLVD CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: 631-273-0900 MAIL ADDRESS: STREET 1: P.O. BOX 18050 STREET 2: 230 MARCUS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: UNITED INTERNATIONAL RESEARCH INC DATE OF NAME CHANGE: 19820422 10-Q 1 ug20210630_10q.htm FORM 10-Q ug20210630_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐	TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

COMMISSION FILE NUMBER: 1-10526

UNITED-GUARDIAN, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		11-1719724
(State or Other Jurisdiction of		(I.R.S. Employer Identification No.)
Incorporation or Organization)

230 Marcus Boulevard, Hauppauge, New York 11788

(Address of Principal Executive Offices)

(631) 273-0900

(Registrant’s Telephone Number)

N/A

(Former name, former address, and former fiscal year, if changed since last report)

Cover Page 1 of 2

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.10 par value per share	UG	NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☑	Smaller reporting company ☑
	Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes ☐ No ☑

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

As of August 1, 2021, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock").

Cover Page 2 of 2

UNITED-GUARDIAN, INC.

INDEX TO FINANCIAL STATEMENTS

	PageNo.
Part I. FINANCIAL INFORMATION

Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise)

Statements of Income - Three and Six Months ended June 30, 2021 and 2020	2

Balance Sheets – June 30, 2021 (unaudited) and December 31, 2020 (audited)	3-4

Statements of Changes in Stockholder’s Equity – Three and Six Months ended June 30, 2021 and 2020	5

Statements of Cash Flows – Six Months ended June 30, 2021 and 2020	6

Notes to Condensed Financial Statements	7-15

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	15-22

Item 3 - Quantitative and Qualitative Disclosures About Market Risk	22

Item 4 - Controls and Procedures	23

Part II. OTHER INFORMATION

Item 1 - Legal Proceedings	23

Item 1A - Risk Factors	23-24

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3 - Defaults Upon Senior Securities	24

Item 4 - Mine Safety Disclosures	24

Item 5 - Other Information	24

Item 6 - Exhibits	25

Signatures	25

Page 1 of 25

UNITED-GUARDIAN, INC.

Part I. FINANCIAL INFORMATION

ITEM 1.

Condensed Financial Statements

STATEMENTS OF INCOME

(unaudited)

	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2021		2020		2021		2020

Net sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

Costs and expenses:
Cost of sales		1,499,390		1,270,434		2,860,403		2,659,765
Operating expenses		513,012		511,635		970,139		1,026,910
Research and development expense		130,025		108,566		218,311		216,298
Total costs and expenses		2,142,427		1,890,635		4,048,853		3,902,973
Income from operations		1,515,551		1,064,009		3,039,993		2,374,585

Other income:
Investment income		45,640		48,319		85,400		92,386
Net gain on marketable securities		137,574		387,179		65,527		30,584
Total other income		183,214		435,498		150,927		122,970
Income before provision for income taxes		1,698,765		1,499,507		3,190,920		2,497,555

Provision for income taxes		354,241		312,896		665,194		520,637
NET INCOME	$	1,344,524	$	1,186,611	$	2,525,726	$	1,976,918

Earnings per common share (basic and diluted)	$	0.29	$	0.26	$	0.55	$	0.43

Weighted average shares (basic and diluted)		4,594,319		4,594,319		4,594,319		4,594,319

See Notes to Condensed Financial Statements

Page 2 of 25

UNITED-GUARDIAN, INC.

BALANCE SHEETS

	JUNE 30,		DECEMBER 31,
	2021		2020
	(unaudited)		(audited)
Current assets:
Cash and cash equivalents	$	744,461	$	591,444
Marketable securities		7,877,825		7,591,381
Accounts receivable, net of allowance for doubtful accounts of $23,695 at June 30, 2021 and $14,017 December 31, 2020		1,965,015		1,387,698
Inventories, net		918,286		1,415,773
Prepaid expenses and other current assets		194,959		161,208
Prepaid income taxes		83,367		99,107
Total current assets		11,783,913		11,246,611

Net property, plant, and equipment:
Land		69,000		69,000
Factory equipment and fixtures		4,553,415		4,516,335
Building and improvements		2,850,263		2,848,585
Total property, plant, and equipment		7,472,678		7,433,920
Less: Accumulated depreciation		6,830,280		6,760,255
Total property, plant, and equipment, net		642,398		673,665
TOTAL ASSETS	$	12,426,311	$	11,920,276

See Notes to Condensed Financial Statements

Page 3 of 25

UNITED-GUARDIAN, INC.

BALANCE SHEETS

(continued)

LIABILITIES AND STOCKHOLDERS’ EQUITY

	JUNE 30,		DECEMBER 31,
	2021		2020
	(unaudited)		(audited)
Current liabilities:
Accounts payable	$	26,003	$	31,800
Accrued expenses and other current liabilities		1,404,725		1,363,457
Dividends payable		19,685		19,028
Total current liabilities		1,450,413		1,414,285

Deferred income taxes, net		301,138		151,684

Commitments and contingencies

Stockholders’ equity:
Common stock $.10 par value, 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		459,432		459,432
Retained earnings		10,215,328		9,894,875
Total stockholders’ equity		10,674,760		10,354,307

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	12,426,311	$	11,920,276

See Notes to Condensed Financial Statements

Page 4 of 25

UNITED-GUARDIAN, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(unaudited)

THREE AND SIX MONTHS ENDED JUNE 30, 2021

	Common stock				Retained
	Shares		Amount		Earnings		Total
Balance, January 1, 2021		4,594,319	$	459,432	$	9,894,875	$	10,354,307
Net income		---		---		1,181,202		1,181,202
Balance, March 31, 2021		4,594,319	$	459,432	$	11,076,077	$	11,535,509
Net income		---		---		1,344,524		1,344,524
Dividends declared and paid ($0.48 per share)		---		---		(2,204,616		(2,204,616	)
Dividends declared but not paid ($0.48 per share)		---		---		(657		(657	)
Balance, June 30, 2021		4,594,319	$	459,432	$	10,215,328	$	10,674,760

THREE AND SIX MONTHS ENDED JUNE 30, 2020

	Common stock				Retained
	Shares		Amount		Earnings		Total
Balance, January 1, 2020		4,594,319	$	459,432	$	10,173,466	$	10,632,898
Net income		---		---		790,307		790,307
Balance, March 31, 2020		4,594,319	$	459,432	$	10,963,773	$	11,423,205
Net income		---		---		1,186,611		1,186,611
Dividends declared and paid ($0.42 per share)		---		---		(1,928,969		(1,928,969	)
Dividends declared but not paid ($0.42 per share)		---		---		(645		(645	)
Balance, June 30, 2020		4,594,319	$	459,432	$	10,220,770	$	10,680,202

See Notes to Condensed Financial Statements

Page 5 of 25

UNITED-GUARDIAN, INC.

STATEMENTS OF CASH FLOWS

(unaudited)

	SIX MONTHS ENDED
	June 30,
	2021			2020
Cash flows from operating activities:
Net income	$	2,525,726		$	1,976,918
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		70,025			81,094
Net gain on marketable securities		(65,527	)		(30,584	)
Allowance for doubtful accounts		9,678			(992	)
Deferred income taxes		149,454			(262,009	)
(Increase) decrease in operating assets:
Accounts receivable		(586,995	)		927,588
Inventories		497,487			(306,115	)
Prepaid expenses and other current assets		(33,751	)		(49,044	)
Prepaid income taxes		15,740			165,300
(Decrease) increase in operating liabilities:
Accounts payable		(5,797	)		24,108
Accrued expenses		41,268			340,486
Income taxes payable		---			317,346
Dividends payable		---			(617	)
Net cash provided by operating activities		2,617,308			3,183,479

Cash flows from investing activities:
Acquisition of property, plant and equipment		(38,758	)		(2,996	)
Proceeds from sale of marketable securities		1,832,827			3,524,156
Purchase of marketable securities		(2,053,744	)		(3,616,962	)
Net cash used in investing activities		(259,675	)		(95,802	)

Cash flows from financing activities:
Dividends paid		(2,204,616	)		(1,928,969	)
Net cash used in financing activities		(2,204,616	)		(1,928,969	)

Net increase in cash and cash equivalents		153,017			1,158,708
Cash and cash equivalents at beginning of period		591,444			1,048,311
Cash and cash equivalents at end of period	$	744,461		$	2,207,019
Supplemental disclosure of cash flow information
Taxes paid	$	300,000		$	300,000
Supplemental disclosure of non-cash dividends payable	$	657		$	645

See Notes to Condensed Financial Statements

Page 6 of 25

UNITED-GUARDIAN, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

1.	Nature of Business

United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients, pharmaceuticals, medical products, and proprietary specialty industrial products. The Company’s research and development department modifies, refines, and expands the uses for existing products for additional uses and markets. It also develops new products using natural and environmentally-friendly raw materials, which is important to many of the Company's cosmetic customers.

2.	Basis of Presentation

Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and six months ended June 30, 2021 (also referred to as the "second quarter of 2021" and the "first half of 2021", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2021. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020.

3.	Impact of Coronavirus (COVID-19)

The significant negative impact that the coronavirus pandemic (“pandemic”) had on the Company’s sales and net income in 2020 abated somewhat during first half of 2021. Although the Company is still experiencing a decline in demand for its cosmetic ingredients compared with demand prior to the pandemic, sales of these products in the second quarter of 2021 were significantly higher than they were in the same period in 2020. The Company believes that sales of these products continue to be negatively impacted by pandemic, particularly in countries where the pandemic is still not under control. This has resulted in a decrease in consumer demand for cosmetics, and a consequent reduced need for the Company’s cosmetic ingredients that are formulated into those products. Until the pandemic situation improves globally, it is likely that sales of the Company’s cosmetic ingredients will continue to be negatively impacted.

Sales of the Company’s non-pharmaceutical medical products (referred to herein as “medical products”) had also been negatively impacted by the pandemic in 2020, but those impacts have lessened as well in the first half of 2021 as both domestic and foreign orders for these products have increased. Sales of the Company’s pharmaceutical products were not impacted by the pandemic in 2020 or in the first six months of 2021.

Page 7 of 25

The pandemic has not significantly affected the ability of the Company to obtain raw materials, and the Company does not anticipate that it will do so in 2021 unless the global pandemic worsens rather than improves. The Company has been able to maintain production throughout the pandemic.

With the continuing uncertainty as to what the duration and future impact of the pandemic will be, the Company is unable to provide an accurate estimate or projection as to what the impact of the pandemic will be on the Company’s operations or its financial results in the future. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic.

4.	Use of Estimates

In preparing financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead.

5.	Cash and Cash Equivalents

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at inception. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At June 30, 2021 and December 31, 2020, $587,000 and $653,000, respectively, exceeded the FDIC limit.

6.	Revenue Recognition

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period that the revenues are recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (‘VA”), rebates in connection with the Company’s current participation in Medicare programs and its past participation in Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

Page 8 of 25

During 2021 and 2020, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell the product at a discounted price. In addition, during 2020, the Company also participated in the Medicaid Drug Rebate Program (MDRP), which required the Company to pay a significant rebate to the various states where Renacidin was provided to Medicaid patients, as well as the Section 340B Drug Pricing Program (340B), which required the Company to sell the product at a deeply discounted price. Due to the overly burdensome nature of the Medicaid rebates, and the deeply discounted pricing associated with the 340B Program, the Company terminated its participation in the MDRP and the 340B Programs, effective December 31, 2020. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

The Company recognizes revenue from sales of its cosmetic ingredients, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer and the Company’s performance obligation is satisfied. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment, which is when the risk of loss and responsibility for the shipment passes to the customer, and the performance obligation of the Company is satisfied. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on prior year historical returns of its pharmaceutical products.

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimated allowances and actual activity.

The timing between recognition of revenue for product sales and the receipt of payment is not significant. Due to the Covid-19 pandemic, the Company experienced minor delays in receiving payments from certain customers that were impacted by the pandemic during the second quarter of 2020, but the negative impact of those delayed payments was not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. As of June 30, 2021 and December 31, 2020, the allowance for doubtful accounts receivable was $23,695 and $14,017, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

Page 9 of 25

The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitles them to distribution and service-related fees. The Company records distribution fees and estimates distribution fees as offsets to revenue.

Disaggregated sales by product class are as follows:

	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Cosmetic ingredients	$	1,855,776	$	1,105,919	$	3,486,372	$	2,808,779
Pharmaceuticals		1,149,179		1,192,441		2,292,487		2,231,152
Medical products		620,748		627,450		1,236,774		1,166,646
Industrial products		32,275		28,834		73,213		70,981
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

The Company’s cosmetic ingredients are marketed worldwide by five marketing partners, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 24% of the Company’s total sales in the second quarter of 2021 were to customers located outside of the United States, compared with approximately 23% in the second quarter of 2020. For the six months ended June 30, 2021 approximately 23% of the Company’s total sales were to customers located outside of the United States, compared with approximately 19% for the six months ended June 30, 2020.

Disaggregated sales by geographic region are as follows:

	Three months ended				Six months ended
	June 30,				June 30,
	2021		2020		2021		2020
United States*	$	2,773,242	$	2,276,962	$	5,444,629	$	5,068,642
Other countries		884,736		677,682		1,644,217		1,208,916
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 72% of its sales of the Company’s products in the second quarter of both 2021 and 2020 were to foreign customers, with China representing approximately 43% of those foreign sales in the second quarter of 2021, compared with approximately 42% in the second quarter of 2020.

For the six months ended June 30, 2021 approximately 69% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 40% of ASI’s sales of the Company’s products, as compared with approximately 69% of ASI’s sales going to customers in other countries for the six months ended June 30, 2020, with China accounting for approximately 34% of ASI’s sales of the Company’s products during that period.

Page 10 of 25

7.	Marketable Securities

Marketable securities include investments in fixed income and equity mutual funds, and U.S. Government securities with maturities greater than 3 months, all of which are reported at their fair values.

The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three- and six-month periods ended June 30, 2021 and June 30, 2020 were as follows:

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2021			2020			2021			2020
Net gains recognized during the period on marketable securities	$	137,574		$	387,179		$	65,527		$	30,584
Less: Net gains recognized during the period on marketable securities sold during the period		(112,180	)		(4,856	)		(112,180	)		(4,856	)
Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date	$	25,394		$	382,323		$	(46,653	)	$	25,728

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

• Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets.

Page 11 of 25

The following tables summarize the Company’s investments:

June 30, 2021 (unaudited)

	Cost		Fair value		Unrealized gain
Equity Securities
Fixed income mutual funds	$	7,211,831	$	7,356,110	$	144,279
Equity and other mutual funds		408,417		521,715		113,298
Total equity securities		7,620,248		7,877,825		257,577
Total marketable securities	$	7,620,248	$	7,877,825	$	257,577

December 31, 2020 (audited)

Equity Securities
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

Investment income is recognized when earned and consists principally of interest income from fixed income mutual funds and U.S Treasury Bills, and dividend income from equity and fixed income mutual funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

Proceeds from the sale and redemption of marketable securities amounted to $1,832,827 for the first half of 2021, which includes realized gains of $112,180. Proceeds from the sale and redemption of marketable securities amounted to $3,524,156 for the first half of 2020, which included realized gains on sales of $4,856.

8.	Inventories

	June 30,		December 31,
	2021		2020
	(unaudited)		(audited)
Inventories consist of the following:
Raw materials	$	408,594	$	415,415
Work in process		114,105		59,258
Finished products		395,587		941,100
Total inventories	$	918,286	$	1,415,773

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at June 30, 2021 and December 31, 2020 are stated net of a reserve of $35,000 for slow moving and obsolete inventory. At June 30, 2021 and December 31, 2020, the Company had allowances of $299,710 and $302,713 respectively, for possible outdated material returns, which is included in accrued expenses.

As of the date of this report, the Covid-19 pandemic has not materially affected the valuation of the Company’s finished products, work in process, or raw material inventories.

Page 12 of 25

9.	Income Taxes

The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of June 30, 2021 and December 31, 2020, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and six months ended June 30, 2021 and 2020, included the following:

	Three months ended June 30,					Six months ended June 30,
	2021		2020			2021		2020
Provision for federal income taxes - current	$	266,780	$	490,893		$	515,640	$	782,496
Provision for state income taxes - current		---		---			100		150
Provision (benefit) for federal income taxes - deferred		87,461		(177,997	)		149,454		(262,009	)
Total provision for Income taxes	$	354,241	$	312,896		$	665,194	$	520,637

10.

Defined Contribution Plan

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions after one year of employment.

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The Company accrued $65,000 in contributions to the DC Plan for the six months ended June 30, 2021, and $72,500 for the six months ended June 30, 2020. For the first half of 2021 and 2020, the Company did not make any discretionary contributions to the DC Plan.

11.

Other Information

	June 30, 2021		December 31, 2020
Accrued Expenses	(unaudited)		(audited)
Bonuses	$	126,000	$	210,000
Distribution fees		340,655		325,792
Payroll and related expenses		272,597		245,521
Reserve for outdated material		299,710		302,713
Deferred revenue		190,164		---
Company 401(k) contribution		65,000		---
Audit fee		35,250		50,500
Annual report expenses		31,497		63,432
Sales rebates		24,213		149,346
Other		19,639		16,153
Total accrued expenses	$	1,404,725	$	1,363,457

Page 13 of 25

12.

Recent Accounting Pronouncements

On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, “Simplifying the Accounting for Income Taxes.” This standard modified ASU 740, and simplifies the accounting for income taxes. The Company has determined that these modifications did not have an impact on its financial statements.

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. In November 2019, the FASB amended the effective date of implementation of this standard for smaller reporting companies. The new effective date is for fiscal years beginning after December 15, 2022. The Company is currently evaluating if this pronouncement will have a potential impact on its financial statements.

13.

Concentrations of Credit Risk

Customer concentration: Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable is low.

During the three months ended June 30, 2021, one of the Company’s cosmetic ingredient marketing partners, along with three of its pharmaceutical distributors, together were responsible for 75% of the Company’s sales, and accounted for 73% of its outstanding accounts receivable at June 30, 2021. During the three months ended June 30, 2020, the same marketing partner and three distributors together were responsible for 76% of the Company’s sales, and accounted for 64% of its outstanding accounts receivable at June 30, 2020.

During the six months ended June 30, 2021, one of the Company’s cosmetic ingredient marketing partners, along with three of its pharmaceutical distributors, together were responsible for 76% of the Company’s sales, and accounted for 73% of its outstanding accounts receivable at June 30, 2021. During the six-month period ended June 30, 2020, the same marketing partner and three distributors together were responsible for 79% of the Company’s sales, and accounted for 64% of its outstanding accounts receivable at June 30, 2020.

14.

Earnings Per Share

Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period, increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

Page 14 of 25

Per share basic and diluted earnings amounted to $0.29 and $0.26 for the three months ended June 30, 2021 and 2020, respectively, and $0.55 and $0.43 for the six months ended June 30, 2021 and 2020, respectively.

15.

Subsequent Events

The Company has evaluated all subsequent events from the date of the financial statements through the date of this report. As detailed in Note 3 above, the Covid-19 pandemic is an ongoing event, and as such, the Company is not able to project or quantify the impact of this event on the Company’s future operations and financial results.

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2020, and a comparison of the results of operations for the second quarter of 2021 and 2020 and the first half of 2021 and 2020. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. All references in this quarterly report to “sales” or “Sales” shall mean “net sales” unless specifically identified as “gross sales”.

FORWARD-LOOKING STATEMENTS

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified by the use of such words as “believes”, “may”, “will”, “should”, “intends”, “plans”, “estimates”, “anticipates”, or other similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; changes in intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices. Accordingly, results achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made.

Page 15 of 25

The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

OVERVIEW

The Company is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, non-pharmaceutical medical products, and proprietary specialty industrial products. All the products that the Company markets, except for Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer.

The Company’s most important product line is its Lubrajel® line of water-based moisturizing and lubricating gels, which are used primarily as ingredients in cosmetic products but are also used in medical products, primarily catheter lubricants. These products are marketed worldwide for cosmetic uses by five marketing partners, each handling a different geographic area, with the largest being U.S.-based ASI. The Company’s research and development department is actively working on the development of new products to expand the Company’s line of cosmetic ingredients. Many of the Company’s products use proprietary manufacturing processes, and the company relies primarily on trade secret protection to protect its intellectual property.

Renacidin and the Company’s other pharmaceutical product, Clorpactin®, which is also used primarily in urology, are distributed through full-line drug wholesalers and marketed only in the United States. Those wholesalers in turn sell the products to pharmacies, hospitals, nursing homes, and other long-term care facilities, and to government agencies, primarily the VA. The Company promotes Renacidin through internet advertising as well as a dedicated website. Clorpactin and some of the Company’s other products are marketed through information provided on the Company’s corporate website.

The Company’s non-pharmaceutical medical products, such as its catheter lubricants, as well as its specialty industrial products, are sold directly to end users, or to contract manufacturers utilized by those end users. They are also available for marketing on a non-exclusive basis by the Company’s marketing partners.

While the Company does have competition in the marketplace for some of its products, particularly its cosmetic ingredients, some of its pharmaceutical and medical products have some unique characteristics, and do not have direct competitors. However, these products may have indirect competition from other products that are not marketed as direct competitors to the Company’s products but may have functionality or properties that are similar to the Company’s products.

The Company recognizes revenue when all of the following requirements are satisfied: (a) persuasive evidence of a sales arrangement exists; (b) products are shipped, which is when the performance obligation is satisfied and title and risk of loss pass to the customers; and (c) collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.

Page 16 of 25

Over the years the Company has been issued many patents and trademarks, and it still maintains several registered trademarks, the two most important of which are “Lubrajel” and “Renacidin.” However, regarding the protection of the Company’s proprietary formulations and manufacturing technology, the Company currently relies primarily on trade secret protection rather than patent protection due to the current disclosure requirements needed to obtain patents, the limited protection they afford, and the difficulty and expense of enforcing them globally. However, the Company may, from time to time, seek patent protection when it believes it would be in the Company’s best interest to do so. All of the Company’s previously issued patents have expired; however, the Company does not believe that the expiration of those patents has had, or will have, any material impact on its sales, since in recent years protection for the Company’s most important products has been based on trade secrets and proprietary manufacturing methods rather than patent protection.

As discussed in Note 3 above, the significant negative impact that the coronavirus pandemic (“pandemic”) had on the Company’s sales and net income in 2020 abated somewhat during first half of 2021. Although the Company is still experiencing a decline in demand for its cosmetic ingredients compared with demand prior to the pandemic, sales of these products in the second quarter of 2021 were significantly higher than they were in the same period in 2020. The Company believes that sales of these products continue to be negatively impacted by the pandemic in countries where the pandemic is still not under control. This has resulted in a decrease in consumer demand for cosmetics, and a consequent reduced need for the Company’s cosmetic ingredients that go into those products. Until the pandemic situation improves globally, it is likely that sales of the Company’s cosmetic ingredients will continue to be negatively impacted.

Sales of the Company’s non-pharmaceutical medical products had also been negatively impacted by the pandemic in 2020, with some medical product customers reducing their purchases, but those impacts have lessened as well in the first half of 2021 as both domestic and foreign orders for these products have increased. As a result, the Company experienced an increase in medical product sales of 6% for the six-month period ended June 30, 2021 compared with the same period in 2020, which was due primarily to increases in sales to the Company’s foreign and domestic customers.

Sales of the Company’s pharmaceutical products were not impacted by the pandemic in 2020 or in the first six months of 2021. However, the Company is beginning to see a small decrease in gross pharmaceutical sales due the termination of its participation in the Medicaid Drug Rebate Program. Please refer to the pharmaceutical sales section of the MD&A for further discussion.

The pandemic has not significantly affected the ability of the Company to obtain raw materials, and the Company does not anticipate that it will do so in 2021 unless the global pandemic worsens rather than improves. The Company has been able to maintain production throughout the pandemic.

With the continuing uncertainty as to what the duration and future impact of the pandemic will be, the Company is unable to provide an accurate estimate or projection as to what the impact of the pandemic will be on the Company’s operations or its financial results in the future. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic.

Page 17 of 25

CRITICAL ACCOUNTING POLICIES

As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2020, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

The Company recognizes revenue from sales of its cosmetic ingredients, medical products, and industrial products when all the following requirements are satisfied: (a) a valid purchase order has been received; (b) products are shipped, which is when the performance obligation is satisfied and title and risk of loss pass to the customers; and (c) future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. The Company assumes responsibility for the shipment arriving at its intended destination. Sales of pharmaceutical products are final and revenue is recognized at the time of shipment, which is when the performance obligation is satisfied. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on gross sales of its pharmaceutical products.

RESULTS OF OPERATIONS

Net Sales

Net sales for the second quarter of 2021 increased by $703,334 (24%) when compared with the same period in 2020. Net sales for the first half of 2021 increased by $811,288 (13%) as compared with the corresponding period in 2020. The increase in sales for both the second quarter of 2021 and the first half of 2021 were attributable to changes in sales of the following product lines:

Cosmetic ingredients:

a) Second quarter sales: For the second quarter of 2021, the Company’s sales of cosmetic ingredients increased by $749,857 (68%) when compared with the second quarter of 2020. The increase in the second quarter sales was due primarily to an increase of $597,964 (72%) in sales of the Company’s cosmetic ingredients to ASI. Based on information provided to the Company by ASI, this increase was due primarily to the resumption of shipments of the Company’s products to China by ASI.

Page 18 of 25

Second quarter sales to the Company’s four other marketing partners, as well as to the four direct cosmetic ingredient customers, increased by a net of $151,893 (56%) compared with the second quarter of 2020. The increase was attributable to a sales increase of $153,165 to the Company’s marketing partner in France and an increase of $11,934 in sales to the Company’s marketing partner in Italy. These increases were offset by a decrease of $9,727 to the Company’s marketing partners in the UK and Switzerland and a decrease of $3,479 to four direct cosmetic ingredient customers.

b) Six-month sales: For the first half of 2021 the Company’s sales of cosmetic ingredients increased by $677,593 (24%) when compared with the equivalent period in 2020. This increase was due primarily to an increase of $503,199 (22%) in shipments of the Company's extensive line of cosmetic ingredients to ASI. The primary reason for the increase in sales for the six-month period was the same as for the sales increase in the second quarter: increased sales to China and other foreign markets by ASI as the economies in various parts of the world begin to emerge from the pandemic.

Sales of the Company’s cosmetic ingredients during the first six months of 2021 to the Company’s four other marketing partners, as well as to the four direct cosmetic ingredient customers, increased by $174,394 (31%) compared with the equivalent period in 2020. The largest increase in sales was to the Company’s marketing partner in the UK, whose sales increased by a total of $74,373; sales to the four direct cosmetic ingredient customers increased by $10,991; and sales to the Company’s marketing partners in Switzerland, Italy and France, increased by a net of $89,030.

The Company believes that the increase in sales of the Company’s cosmetic ingredients in Europe was, at least in part, the result of global pandemic conditions improving.

Pharmaceuticals:

Because there are fees, rebates and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin, discussion of the Company’s pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances). Gross sales of the Company’s pharmaceutical products for the three- and six-month periods ended June 30, 2021 decreased by $120,215 (8%) and $86,054 (3%), respectively, compared with the corresponding periods in 2020. These decreases were due primarily to decreases of $158,630 (12%) and $145,741 (6%) in gross sales of Renacidin for the three- and six-month periods, respectively, ended June 30, 2021. These decreases were partially offset by increases of $38,415 (28%) and $59,687 (22%) in gross sales of the Company’s other pharmaceutical product, Clorpactin, for the same three- and six-month periods, respectively, which the Company believes was most likely due to normal fluctuations in the sales of Clorpactin.

The decrease in gross sales for the three- and six-month periods ended June 30, 2021 was partially offset by a decrease in fees, rebates and allowances of $76,954 (26%) and $147,390 (24%), respectively. The decrease in these fees, rebates and allowances was the result of the Company’s termination of its participation in the Medicaid Drug Rebate Program at the end of 2020. Due to the overly burdensome nature of the state Medicaid rebates that the Company had to pay under this program, the Company determined that it was no longer profitable for the Company to continue to participate. Accordingly, on October 30, 2020 the Company informed the Centers for Medicare & Medicaid Services (CMS) of its intention to terminate its Medicaid Drug Rebate Agreement and its participation in the Medicaid Program, effective December 31, 2020. As the Company had anticipated, the discontinuation of its participation in this program resulted in the loss of some Renacidin sales, but that loss was more than offset by the elimination of the rebate payments, which resulted in an increase in net income.

Page 19 of 25

As sales of the Company’s pharmaceutical products fluctuate, there is typically a corresponding direct relationship in the related allowances, such as for distribution fees, VA chargebacks, Medicare rebates, sales rebates and discounts, outdated material returns, and Medicaid rebates. For the three- and six-month periods ended June 30, 2021, these allowances decreased by $76,954 (26%) and $147,390 (24%), respectively, compared with the same periods in 2020. This was primarily a result of the Company’s termination of its participation in the Medicaid Program. Although the Company will no longer be incurring Medicaid-related rebate costs, it will continue to incur costs related to other allowances, including Medicare rebates, distribution fees, chargebacks on VA sales, and outdated material returns.

Medical (non-pharmaceutical) products:

Sales of the Company’s medical products for the three-month period ended June 30, 2021, decreased by $6,702 (1%) and increased by $70,128 (6%), for the six-month period ended June 30, 2021. The decrease in sales for the three-month period was primarily attributable to the loss of one of the Company’s domestic medical product customers, which had reformulated the product in which the Company’s product had been used. However, due to some of the Company’s other medical customers located outside the United States increasing their orders due to pandemic conditions improving, the impact of the loss of that customer was not as severe for the three-month period. For the six-month period ended June 30, 2021, the increase in medical product sales was primarily due to increased orders from the Company’s foreign and domestic customers, which began to place larger orders than they had in 2020 as a result of improving global conditions related to the coronavirus pandemic.

Industrial and other products:

Sales of the Company's industrial products, as well as other miscellaneous products, for the three- and six-month periods ended June 30, 2021, increased by $3,441 (12%) and $2,232 (3%), respectively, when compared with the corresponding periods in 2020. The increase in sales for both periods was primarily due to an increase in orders from two of the Company’s industrial product customers whose orders had decreased or ceased during the same periods in 2020 due to the coronavirus pandemic. The Company believes that if the pandemic conditions improve, orders of these products should resume their pre-pandemic levels.

Cost of Sales

Cost of sales as a percentage of net sales decreased to 41% in the second quarter of 2021 from 43% in the second quarter of 2020. For the first six months of 2021, cost of sales as a percentage of sales decreased to 40% compared with 42% for the first six months of 2020. The decreases in both periods were the result of a combination of lower overhead costs and the product mix. Both periods in 2021 saw decreased sales of Renacidin, which has a higher production cost compared to the Company’s line of Lubrajel products, the sales of which began to increase in the first quarter of 2021 as the result of the improving global pandemic conditions.

Page 20 of 25

Operating Expenses

Operating expenses, consisting of selling and general and administrative expenses, remained relatively consistent, increasing by only $1,377 (less than 1%) for the second quarter of 2021 compared with the equivalent period in 2020. Operating expenses decreased by $56,771 (6%) for the first six months of 2021, compared with comparable periods in 2020. The decrease in operating expenses for the first six months of 2021 was primarily due to decreases in payroll and payroll related expenses and certain employee fringe benefit costs. Operating expenses are expected to remain relatively consistent for the remainder of the year.

Research and Development Expenses

Research and development expenses increased by $21,459 (20%) for the second quarter of 2021 compared with the second quarter of 2020, and increased by $2,013 (1%) for the first six months of 2021 compared with the first six months of 2020. The increases in both periods were due primarily to an increase in payroll and payroll related expenses.

Investment Income

Investment income decreased by $2,679 (6%) for the second quarter of 2021 compared with the second quarter of 2020, and decreased by $6,986 (8%) for the first half of 2021 compared with the same period in 2020. These decreases were due to a decrease in dividend income from stock and bond mutual funds compared with the same periods in 2020.

Net Gain on Marketable Securities

Net gain on marketable securities decreased by $249,605 (64%) for the second quarter of 2021 compared with the second quarter of 2020. In the second quarter of 2020, the Company had recognized an a unusually large unrealized gain of $383,323, which was the result of the market rebounding after the negative impact the Coronavirus pandemic had on the stock and bond markets in the first quarter of 2020. Those markets took a steep drop in the first few weeks of 2020 after COVID-19 reached the United States. In the second quarter of 2020 the stock market rebounded, which resulted in the significant unrealized gains that the Company experienced in that quarter. There was no comparable significant fluctuation in the stock and bond markets in the first six months of 2021.

For the first half of 2021, the net gain on marketable securities increased by $34,943 (114%), compared with the same period in 2020. The primary reason for the increase was that during the first six months of 2021, the Company recognized a realized gain on the sale of marketable securities in the amount of $112,180 compared with the comparable six-month period in 2020, where the realized gain on securities sold was $4,856.

Provision for Income Taxes

The Company's effective income tax rate was 21% for the first halves and second quarters of 2021 and 2020. The Company’s tax rate is expected to remain at 21% for the current fiscal year.

Page 21 of 25

LIQUIDITY AND CAPITAL RESOURCES

Working capital increased from $9,832,326 at December 31, 2020 to $10,333,500 at June 30, 2021, an increase of $501,174. The current ratio increased from 8.0 to 1 at December 31, 2020 to 8.1 to 1 at June 30, 2021. The increase in working capital and the current ratio was primarily due to increases in cash, marketable securities, and accounts receivable, offset by a decrease in inventories.

The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any significant capital expenditures for the remainder of 2021. The Company intends to utilize its available cash and assets primarily for its continued organic growth and potential future strategic transactions, as well as to mitigate the potential impact of COVID-19 on the Company's business.

The Company generated cash from operations of $2,617,308 and $3,183,479 for the first half of 2021 and 2020, respectively. The decrease from 2020 to 2021 was primarily due to an increase in accounts receivable.

Cash used in investing activities was $259,675 and $95,802 for the first half of 2021 and 2020, respectively. The increase was due primarily to the timing of marketable security sales and reinvestments in 2021 compared with 2020.

Cash used in financing activities was $2,204,616 and $1,928,969 for the first half of 2021 and 2020, respectively. The increase was due to an increase in dividends paid from $0.42 per share in 2020 to $0.48 per share in 2021.

The Company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of other opportunities that may arise that are in the best interest of the Company and its shareholders.

OFF BALANCE-SHEET ARRANGEMENTS

The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future impact on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The information to be reported under this item is not required of smaller reporting companies.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information to be reported under this item is not required of smaller reporting companies.

Page 22 of 25

Item 4.

CONTROLS AND PROCEDURES.

(a)

DISCLOSURE CONTROLS AND PROCEDURES

The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

(b)

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

NONE

ITEM 1A.

RISK FACTORS.

IMPACT OF COVID-19

As a result of the coronavirus pandemic, global consumer purchases of cosmetic products declined significantly in 2020, which resulted in a significant decline in sales of the Company’s cosmetic ingredients in the last three quarters of 2020. Sales of these products were particularly impacted in China, where prior to the pandemic the Company had significant sales. This resulted in an excess inventory situation in China, which severely impacted sales, and which was not resolved until the end of 2020.

Page 23 of 25

The impact of the pandemic on the Company’s sales has lessened in 2021. While sales of its cosmetic products in the first quarter of 2021 were slightly lower than in the first quarter of 2020, that was because the pandemic didn’t begin to significantly impact sales of the Company’s cosmetic products until the second quarter of 2020, and that impact continued into the first quarter of 2021.

With the pandemic now beginning to abate, sales of these products in the second quarter of 2021 increased significantly compared with the second quarter of 2020. It is still too early to predict what the continuing impact of the pandemic will be on future sales of these products. Until the global pandemic situation improves, it is likely that sales of the Company’s cosmetic ingredients will continue to be negatively impacted, but to a lesser degree than they were in the last three quarters of 2020. Due to the uncertainty surrounding the duration of the pandemic and its impact on the various countries in which the Company does business, the Company is unable to provide an accurate estimate or projection as to what the impact of the pandemic will continue to be on the Company’s operations and financial results. While the pandemic also negatively impacted sales of the Company’s medical products, it has not impacted sales of its pharmaceutical products.

The Company does not anticipate that the coronavirus pandemic will affect its ability to obtain raw materials and maintain production, and the Company has multiple sources for many of its raw materials. However, some of the Company’s raw materials have experienced price increases, which will impact the manufacturing cost of some of the Company’s products. The Company may or may not be able to pass along and recoup these price increases, depending on the product. The Company expects to be able to maintain production levels sufficient to ship orders on a timely basis.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

NONE

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

NONE

ITEM 4.

MINE SAFETY DISCLOSURES.

NONE

ITEM 5.

OTHER INFORMATION.

NONE

Page 24 of 25

ITEM 6.

EXHIBITS.

31.1*	Certification of Ken Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*	Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32*	Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*	Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*	Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1).

* Filed herewith

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UNITED-GUARDIAN, INC.
	(Registrant)


	By:	/S/ KENNETH H. GLOBUS
		Kenneth H. Globus
		President


	By:	/S/ ANDREA J. YOUNG
Date: August 10, 2021		Andrea J. Young
		Chief Financial Officer

Page 25 of 25

EX-31.1 2 ex_272617.htm EXHIBIT 31.1 ex_272617.htm

EXHIBIT 31.1

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Ken Globus, certify that:

1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended June 30, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2021	By:	/s/ Ken Globus
		Ken Globus
		President and Principal Executive Officer

EX-31.2 3 ex_272618.htm EXHIBIT 31.2 ex_272618.htm

EXHIBIT 31.2

SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Andrea Young, certify that:

1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended June 30, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2021	By:	/s/ Andrea Young
		Andrea Young
		Principal Financial Officer

EX-32 4 ex_272619.htm EXHIBIT 32 ex_272619.htm

EXHIBIT 32

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of United-Guardian, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the Securities and Exchange Commission (the "Report"), I, Ken Globus, President and Principal Executive Officer of the Company, and I, Andrea Young, Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 10, 2021	By:	/s/ Ken Globus
		Ken Globus
		President & Principal Executive Officer

	By:	/s/ Andrea Young
		Andrea Young
		Principal Financial Officer

EX-101.SCH 5 ug-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Statements of Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Impact of Coronavirus (COVID-19) link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Use of Estimates link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Cash and cash Equivalents link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Inventories link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Defined Contribution Plan link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Other Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Concentrations of Credit Risk link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 15 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 6 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 7 - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 8 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 9 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 11 - Other Information (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Cash and cash Equivalents (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Revenue Recognition - Disaggregated Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 7 - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Marketable Securities - Summary of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 8 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 9 - Income Taxes - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 10 - Defined Contribution Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 11 - Other Information - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 13 - Concentrations of Credit Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 ug-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ug-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ug-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Note 6 - Revenue Recognition ug_AccruedDistributionFeesCurrent Distribution fees Accrued distribution fees Use of Estimates Disclosure [Text Block] The entire disclosure for use of estimates. Note 7 - Marketable Securities Note 8 - Inventories Note 9 - Income Taxes Note 11 - Other Information Note 6 - Revenue Recognition - Disaggregated Revenue (Details) Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Note 7 - Marketable Securities - Summary of Investments (Details) Income Tax Disclosure [Text Block] Note 8 - Inventories - Summary of Inventories (Details) Discretionary Contributions Vesting Each Additional Year [Member] Represents discretionary contributions vesting each additional year of employment. Note 9 - Income Taxes - Provision for Income Taxes (Details) Discretionary Contributions Vesting at Two Years [Member] Represents discretionary contributions vesting after two years of employment. Note 11 - Other Information - Summary of Accrued Expenses (Details) Notes To Financial Statements us-gaap_LiabilitiesCurrent Total current liabilities Notes To Financial Statements [Abstract] Medical Product [Member] Represents the information pertaining to medical product. Equity securities, unrealized gain Accumulated amount of unrealized gain (loss) on equity securities. Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Equity securities, cost Fixed Income Securities [Member] Depreciation and amortization us-gaap_AssetsCurrent Total current assets Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date Common stock $.10 par value, 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities Retirement Plan Name [Axis] Financial Instruments [Domain] Retirement Plan Name [Domain] Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Financial Instrument [Axis] Common stock, par value (in dollars per share) Accrued expenses and other current liabilities Total accrued expenses Dividends payable Accounts payable Product and Service [Axis] Product and Service [Domain] us-gaap_AccruedBonusesCurrent Bonuses us-gaap_OtherAccruedLiabilitiesCurrent Other Prepaid income taxes us-gaap_AccruedSalariesCurrent Payroll and related expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Geographical [Axis] Geographical [Domain] Impact of Coronavirus (COVID-19) [Text Block] The entire disclosure pertaining to impact of coronavirus (COVID-19). Inventories, net Total inventories us-gaap_AccruedProfessionalFeesCurrent Audit fee us-gaap_AccruedMarketingCostsCurrent Sales rebates Net Sales Net sales us-gaap_InventoryValuationReserves Inventory Valuation Reserves, Ending Balance us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Acquisition of property, plant and equipment Customer [Axis] Customer [Domain] Taxes paid Net gains recognized during the period on marketable securities Equity And Other Mutual Funds [Member] Equity And Other Mutual Funds Member us-gaap_Assets TOTAL ASSETS Supplemental disclosure of cash flow information Pharmaceuticals [Member] Net property, plant, and equipment: Cash flows from operating activities: Industrial And Other [Member] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, net of allowance for doubtful accounts of $23,695 at June 30, 2021 and $14,017 December 31, 2020 us-gaap_MarketableSecuritiesCurrent Marketable securities Stockholders’ equity: us-gaap_NonoperatingIncomeExpense Total other income Current assets: Investment income Net income NET INCOME us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies us-gaap_OperatingIncomeLoss Income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other income: Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Cost of sales ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) Represents the vesting period of discretionary contributions made under the defined contribution plan. us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities Company 401(k) contribution Deferred income taxes, net Less: Accumulated depreciation us-gaap_PropertyPlantAndEquipmentNet Total property, plant, and equipment, net us-gaap_PropertyPlantAndEquipmentGross Total property, plant, and equipment ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss Marketable securities, unrealized gain Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities. Land us-gaap_Dividends Dividends Supplemental disclosure of non-cash dividends payable ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue Marketable securities Fair value of investment in debt securities classified as held to maturity and equity securities. ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost Marketable securities, cost Cost of investment in debt securities classified as held to maturity and equity securities. Building and improvements Factory equipment and fixtures Other Liabilities Disclosure [Text Block] us-gaap_PaymentsOfDividends Dividends paid us-gaap_CostsAndExpenses Total costs and expenses Cash flows from investing activities: Scenario [Domain] Retained Earnings [Member] Earnings Per Share [Text Block] Equity securities Net gain on marketable securities Provision for state income taxes - current Scenario [Axis] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable us-gaap_MarketableSecuritiesRealizedGainLoss Net gain on marketable securities Common Stock [Member] Provision for federal income taxes - current Provision (benefit) for federal income taxes - deferred us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income before provision for income taxes us-gaap_IncomeTaxExpenseBenefit Total provision for Income taxes Provision for income taxes Accrued expenses Equity Components [Axis] Equity Component [Domain] CHINA Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Gain (Loss) on Securities [Table Text Block] us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DeferredRevenueCurrent Deferred revenue us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Cash and cash equivalents Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Accounting Policies [Abstract] Distributors and Marketing Partners [Member] Represents distributors and marketing partners of the company. Document Transition Report City Area Code Concentration Risk Disclosure [Text Block] Entity Interactive Data Current Dividends declared per share (in dollars per share) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date (Decrease) increase in operating liabilities: us-gaap_DebtAndEquitySecuritiesRealizedGainLoss Debt and Equity Securities, Realized Gain (Loss), Total Less: Net gains recognized during the period on marketable securities sold during the period us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Basis of Accounting [Text Block] Document Fiscal Period Focus Document Fiscal Year Focus Marketing Partner [Member] Information pertaining to the marking partner. Document Period End Date Distributor [Member] Information pertaining to the distributor. Entity File Number us-gaap_IncreaseDecreaseInPrepaidTaxes Prepaid income taxes Entity Emerging Growth Company Document Type Cosmetic Ingredients [Member] Represents information related to cosmetic ingredients. Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status ug_IncreaseDecreaseInDividendsPayable Dividends payable The increase (decrease) during the reporting period in dividends payable. Weighted average shares (basic and diluted) (in shares) us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Non-US [Member] Earnings per common share (basic and diluted) (in dollars per share) Earnings Per Share, Basic and Diluted, Total (in dollars per share) Entity Central Index Key Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance EX-101.PRE 9 ug-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 ug20210630_10q_htm.xml IDEA: XBRL DOCUMENT 0000101295 2021-01-01 2021-06-30 0000101295 2021-08-01 0000101295 2021-04-01 2021-06-30 0000101295 2020-04-01 2020-06-30 0000101295 2020-01-01 2020-06-30 0000101295 2021-06-30 0000101295 2020-12-31 0000101295 us-gaap:CommonStockMember 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000101295 2021-01-01 2021-03-31 0000101295 us-gaap:CommonStockMember 2021-03-31 0000101295 us-gaap:RetainedEarningsMember 2021-03-31 0000101295 2021-03-31 0000101295 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendPaidMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendDeclaredMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 us-gaap:CommonStockMember 2021-06-30 0000101295 us-gaap:RetainedEarningsMember 2021-06-30 0000101295 us-gaap:CommonStockMember 2019-12-31 0000101295 us-gaap:RetainedEarningsMember 2019-12-31 0000101295 2019-12-31 0000101295 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000101295 2020-01-01 2020-03-31 0000101295 us-gaap:CommonStockMember 2020-03-31 0000101295 us-gaap:RetainedEarningsMember 2020-03-31 0000101295 2020-03-31 0000101295 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendPaidMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendDeclaredMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 us-gaap:CommonStockMember 2020-06-30 0000101295 us-gaap:RetainedEarningsMember 2020-06-30 0000101295 2020-06-30 0000101295 us-gaap:DividendDeclaredMember 2021-01-01 2021-06-30 0000101295 us-gaap:DividendDeclaredMember 2020-01-01 2020-06-30 0000101295 ug:CosmeticIngredientsMember 2021-04-01 2021-06-30 0000101295 ug:CosmeticIngredientsMember 2020-04-01 2020-06-30 0000101295 ug:CosmeticIngredientsMember 2021-01-01 2021-06-30 0000101295 ug:CosmeticIngredientsMember 2020-01-01 2020-06-30 0000101295 ug:PharmaceuticalsMember 2021-04-01 2021-06-30 0000101295 ug:PharmaceuticalsMember 2020-04-01 2020-06-30 0000101295 ug:PharmaceuticalsMember 2021-01-01 2021-06-30 0000101295 ug:PharmaceuticalsMember 2020-01-01 2020-06-30 0000101295 ug:MedicalProductMember 2021-04-01 2021-06-30 0000101295 ug:MedicalProductMember 2020-04-01 2020-06-30 0000101295 ug:MedicalProductMember 2021-01-01 2021-06-30 0000101295 ug:MedicalProductMember 2020-01-01 2020-06-30 0000101295 ug:IndustrialAndOtherMember 2021-04-01 2021-06-30 0000101295 ug:IndustrialAndOtherMember 2020-04-01 2020-06-30 0000101295 ug:IndustrialAndOtherMember 2021-01-01 2021-06-30 0000101295 ug:IndustrialAndOtherMember 2020-01-01 2020-06-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0000101295 country:US 2021-04-01 2021-06-30 0000101295 country:US 2020-04-01 2020-06-30 0000101295 country:US 2021-01-01 2021-06-30 0000101295 country:US 2020-01-01 2020-06-30 0000101295 us-gaap:NonUsMember 2021-04-01 2021-06-30 0000101295 us-gaap:NonUsMember 2020-04-01 2020-06-30 0000101295 us-gaap:NonUsMember 2021-01-01 2021-06-30 0000101295 us-gaap:NonUsMember 2020-01-01 2020-06-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0000101295 us-gaap:FixedIncomeSecuritiesMember 2021-06-30 0000101295 ug:EquityAndOtherMutualFundsMember 2021-06-30 0000101295 us-gaap:FixedIncomeSecuritiesMember 2020-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2020-12-31 0000101295 ug:DCPlanMember 2021-01-01 2021-06-30 0000101295 ug:DiscretionaryContributionsVestingAtTwoYearsMember ug:DCPlanMember 2021-01-01 2021-06-30 0000101295 ug:DiscretionaryContributionsVestingEachAdditionalYearMember ug:DCPlanMember 2021-01-01 2021-06-30 0000101295 ug:DCPlanMember 2020-01-01 2020-06-30 0000101295 ug:MarketingPartnerMember 2021-04-01 2021-06-30 0000101295 ug:DistributorMember 2021-04-01 2021-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000101295 ug:DistributorMember 2020-04-01 2020-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0000101295 ug:MarketingPartnerMember 2021-01-01 2021-06-30 0000101295 ug:DistributorMember 2021-01-01 2021-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember 2020-01-01 2020-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 iso4217:USD iso4217:USD shares pure utr:Y 0000101295 UNITED GUARDIAN INC false --12-31 Q2 2021

23695

14017

0.10

10000000

4594319

0.48

0.42

0.72

35000

P1Y P2Y P6Y

1 3 3 1 3 3 10-Q true 2021-06-30 false 1-10526 DE 11-1719724 230 Marcus Boulevard Hauppauge NY 11788 631 273-0900 Common Stock, $0.10 par value per share UG NASDAQ Yes Yes Non-accelerated Filer true false false 4594319

3657978

2954644

7088846

6277558

1499390

1270434

2860403

2659765

513012

511635

970139

1026910

130025

108566

218311

216298

2142427

1890635

4048853

3902973

1515551

1064009

3039993

2374585

45640

48319

85400

92386

137574

387179

65527

30584

183214

435498

150927

122970

1698765

1499507

3190920

2497555

354241

312896

665194

520637

1344524

1186611

2525726

1976918

0.29

0.26

0.55

0.43

4594319

744461

591444

7877825

7591381

1965015

1387698

918286

1415773

194959

161208

83367

99107

11783913

11246611

69000

4553415

4516335

2850263

2848585

7472678

7433920

6830280

6760255

642398

673665

12426311

11920276

26003

31800

1404725

1363457

19685

19028

1450413

1414285

301138

151684

459432

10215328

9894875

10674760

10354307

12426311

11920276

4594319

459432

9894875

10354307

1181202

4594319

459432

11076077

11535509

1344524

2204616

657

4594319

459432

10215328

10674760

4594319

459432

10173466

10632898

790307

4594319

459432

10963773

11423205

1186611

1928969

645

4594319

459432

10220770

10680202

2525726

1976918

70025

81094

65527

30584

9678

-992

149454

-262009

586995

-927588

-497487

306115

33751

49044

-15740

-165300

-5797

24108

41268

340486

317346

-617

2617308

3183479

38758

2996

1832827

3524156

2053744

3616962

-259675

-95802

2204616

1928969

-2204616

-1928969

153017

1158708

591444

1048311

744461

2207019

300000

657

645

587000

653000

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> 6. </td><td style="width: auto;"> Revenue Recognition </td></tr> </tbody></table> The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales. The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period that the revenues are recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (‘VA”), rebates in connection with the Company’s current participation in Medicare programs and its past participation in Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period. During 2021 and 2020, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell the product at a discounted price. In addition, during 2020, the Company also participated in the Medicaid Drug Rebate Program (MDRP), which required the Company to pay a significant rebate to the various states where Renacidin was provided to Medicaid patients, as well as the Section 340B Drug Pricing Program (340B), which required the Company to sell the product at a deeply discounted price. Due to the overly burdensome nature of the Medicaid rebates, and the deeply discounted pricing associated with the 340B Program, the Company terminated its participation in the MDRP and the 340B Programs, effective December 31, 2020. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized. The Company recognizes revenue from sales of its cosmetic ingredients, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer and the Company’s performance obligation is satisfied. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment, which is when the risk of loss and responsibility for the shipment passes to the customer, and the performance obligation of the Company is satisfied. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on prior year historical returns of its pharmaceutical products. The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party. Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimated allowances and actual activity. The timing between recognition of revenue for product sales and the receipt of payment is not significant. Due to the Covid-19 pandemic, the Company experienced minor delays in receiving payments from certain customers that were impacted by the pandemic during the second quarter of 2020, but the negative impact of those delayed payments was not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. As of June 30, 2021 and December 31, 2020, the allowance for doubtful accounts receivable was $23,695 and $14,017, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken. The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitles them to distribution and service-related fees. The Company records distribution fees and estimates distribution fees as offsets to revenue. Disaggregated sales by product class are as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Three months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Six months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Cosmetic ingredients </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,855,776</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,105,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,486,372</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,808,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceuticals </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,149,179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,192,441</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,292,487</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,231,152</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical products </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">620,748</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">627,450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,236,774</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,166,646</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Industrial products </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,275</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,834</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,213</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 2pt; border-bottom: 1px solid rgb(0, 0, 0);">70,981</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,657,978</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,954,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,088,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,277,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> The Company’s cosmetic ingredients are marketed worldwide by five marketing partners, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 24% of the Company’s total sales in the second quarter of 2021 were to customers located outside of the United States, compared with approximately 23% in the second quarter of 2020. For the six months ended June 30, 2021 approximately 23% of the Company’s total sales were to customers located outside of the United States, compared with approximately 19% for the six months ended June 30, 2020. Disaggregated sales by geographic region are as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three months ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Six months ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> United States* </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,773,242</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,276,962</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,444,629</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,068,642</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other countries </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">884,736</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">677,682</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,644,217</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,208,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,657,978</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,954,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,088,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,277,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> * </td><td style="width: auto;"> Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 72% of its sales of the Company’s products in the second quarter of both 2021 and 2020 were to foreign customers, with China representing approximately 43% of those foreign sales in the second quarter of 2021, compared with approximately 42% in the second quarter of 2020. </td></tr> </tbody></table> For the six months ended June 30, 2021 approximately 69% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 40% of ASI’s sales of the Company’s products, as compared with approximately 69% of ASI’s sales going to customers in other countries for the six months ended June 30, 2020, with China accounting for approximately 34% of ASI’s sales of the Company’s products during that period.

23695

14017

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Three months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Six months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Cosmetic ingredients </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,855,776</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,105,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,486,372</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,808,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceuticals </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,149,179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,192,441</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,292,487</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,231,152</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical products </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">620,748</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">627,450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,236,774</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,166,646</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Industrial products </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,275</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,834</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,213</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 2pt; border-bottom: 1px solid rgb(0, 0, 0);">70,981</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,657,978</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,954,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,088,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,277,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>

1855776

1105919

3486372

2808779

1149179

1192441

2292487

2231152

620748

627450

1236774

1166646

32275

28834

73213

70981

3657978

2954644

7088846

6277558

0.24

0.23

0.19

2773242

2276962

5444629

5068642

884736

677682

1644217

1208916

3657978

2954644

7088846

6277558

0.72

0.43

0.42

0.69

0.40

0.69

0.34

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> 7. </td><td style="width: auto;"> Marketable Securities </td></tr> </tbody></table> Marketable securities include investments in fixed income and equity mutual funds, and U.S. Government securities with maturities greater than 3 months, all of which are reported at their fair values. The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three- and six-month periods ended June 30, 2021 and June 30, 2020 were as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> THREE MONTHS ENDED JUNE 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 27pt;"> SIX MONTHS ENDED JUNE 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Net gains recognized during the period on marketable securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">387,179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65,527</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,584</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Net gains recognized during the period on marketable securities sold during the period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112,180</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,856</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112,180</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,856</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,394</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">382,323</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(46,653</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,728</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement. The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments: June 30, 2021 (unaudited) <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: center;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair value </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%;">Equity Securities</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,211,831</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,356,110</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">144,279</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">408,417</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">521,715</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,298</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,620,248</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,877,825</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">257,577</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,620,248</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,877,825</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">257,577</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> December 31, 2020 (audited) <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Equity Securities </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,703,107</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,907,270</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">204,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">584,044</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">684,111</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,067</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> Investment income is recognized when earned and consists principally of interest income from fixed income mutual funds and U.S Treasury Bills, and dividend income from equity and fixed income mutual funds. Realized gains and losses on sales of investments are determined on a specific identification basis. Proceeds from the sale and redemption of marketable securities amounted to $1,832,827 for the first half of 2021, which includes realized gains of $112,180. Proceeds from the sale and redemption of marketable securities amounted to $3,524,156 for the first half of 2020, which included realized gains on sales of $4,856.

137574

387179

65527

30584

112180

4856

112180

4856

25394

382323

-46653

25728

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: center;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair value </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%;">Equity Securities</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,211,831</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,356,110</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">144,279</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">408,417</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">521,715</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,298</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,620,248</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,877,825</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">257,577</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,620,248</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,877,825</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">257,577</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Equity Securities </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,703,107</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,907,270</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">204,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">584,044</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">684,111</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,067</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>

7211831

7356110

144279

408417

521715

113298

7620248

7877825

257577 7620248 7877825 257577

6703107

6907270

204163

584044

684111

100067

7287151

7591381

304230 7287151 7591381 304230

1832827

112180

3524156

4856

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> (unaudited) </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> (audited) </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Inventories consist of the following: </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Raw materials </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">408,594</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">415,415</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Work in process </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">114,105</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">59,258</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Finished products </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">395,587</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">941,100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total inventories </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">918,286</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,415,773</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>

408594

415415

114105

59258

395587

941100

918286

1415773

35000

299710 302713

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Three months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Six months ended June 30,</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Provision for federal income taxes - current </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">266,780</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">490,893</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">515,640</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">782,496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision for state income taxes - current </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 27pt;">---</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 27pt;">100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 29pt;">150</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision (benefit) for federal income taxes - deferred </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">87,461</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">(177,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">149,454</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 29pt; border-bottom: 1px solid rgb(0, 0, 0);">(262,009</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total provision for Income taxes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">354,241</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">312,896</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">665,194</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">520,637</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>

266780

490893

515640

782496

100

150

87461

-177997

149454

-262009

354241

312896

665194

520637

0.04

0.20

65000

72500

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> June 30, 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, 2020 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Accrued Expenses </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (unaudited) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (audited) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Bonuses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">126,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">210,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Distribution fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">340,655</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">325,792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Payroll and related expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">272,597</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">245,521</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Reserve for outdated material </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">299,710</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">302,713</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deferred revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,164</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Company 401(k) contribution </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Audit fee </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">50,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Annual report expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,497</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63,432</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Sales rebates </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,213</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">149,346</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,153</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total accrued expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,404,725</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,363,457</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>

126000

210000

340655 325792

272597

245521

299710 302713

190164

65000

35250

50500

31497 63432

24213

149346

19639

16153

1404725

1363457

0.75

0.73

0.76

0.64

0.76

0.73

0.79

0.64

0.29

0.26

0.55

0.43

Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 72% of its sales of the Company’s products in the second quarter of both 2021 and 2020 were to foreign customers, with China representing approximately 43% of those foreign sales in the second quarter of 2021, compared with approximately 42% in the second quarter of 2020.

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2021	Aug. 01, 2021
Document Information [Line Items]
Entity Central Index Key	0000101295
Entity Registrant Name	UNITED GUARDIAN INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	1-10526
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-1719724
Entity Address, Address Line One	230 Marcus Boulevard
Entity Address, City or Town	Hauppauge
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11788
City Area Code	631
Local Phone Number	273-0900
Title of 12(b) Security	Common Stock, $0.10 par value per share
Trading Symbol	UG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,594,319

XML 12 R2.htm IDEA: XBRL DOCUMENT

Statements of Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
Statements of Income (Unaudited) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net sales	$ 3,657,978	$ 2,954,644	$ 7,088,846	$ 6,277,558
Costs and expenses:
Cost of sales	1,499,390	1,270,434	2,860,403	2,659,765
Operating expenses	513,012	511,635	970,139	1,026,910
Research and development expense	130,025	108,566	218,311	216,298
Total costs and expenses	2,142,427	1,890,635	4,048,853	3,902,973
Income from operations	1,515,551	1,064,009	3,039,993	2,374,585
Other income:
Investment income	45,640	48,319	85,400	92,386
Net gain on marketable securities	137,574	387,179	65,527	30,584
Total other income	183,214	435,498	150,927	122,970
Income before provision for income taxes	1,698,765	1,499,507	3,190,920	2,497,555
Provision for income taxes	354,241	312,896	665,194	520,637
NET INCOME	$ 1,344,524	$ 1,186,611	$ 2,525,726	$ 1,976,918
Earnings per common share (basic and diluted) (in dollars per share)	$ 0.29	$ 0.26	$ 0.55	$ 0.43
Weighted average shares (basic and diluted) (in shares)	4,594,319	4,594,319	4,594,319	4,594,319

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 744,461	$ 591,444
Marketable securities	7,877,825	7,591,381
Accounts receivable, net of allowance for doubtful accounts of $23,695 at June 30, 2021 and $14,017 December 31, 2020	1,965,015	1,387,698
Inventories, net	918,286	1,415,773
Prepaid expenses and other current assets	194,959	161,208
Prepaid income taxes	83,367	99,107
Total current assets	11,783,913	11,246,611
Net property, plant, and equipment:
Land	69,000	69,000
Factory equipment and fixtures	4,553,415	4,516,335
Building and improvements	2,850,263	2,848,585
Total property, plant, and equipment	7,472,678	7,433,920
Less: Accumulated depreciation	6,830,280	6,760,255
Total property, plant, and equipment, net	642,398	673,665
TOTAL ASSETS	12,426,311	11,920,276
Accounts payable	26,003	31,800
Accrued expenses and other current liabilities	1,404,725	1,363,457
Dividends payable	19,685	19,028
Total current liabilities	1,450,413	1,414,285
Deferred income taxes, net	301,138	151,684
Commitments and contingencies
Stockholders’ equity:
Common stock $.10 par value, 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	459,432	459,432
Retained earnings	10,215,328	9,894,875
Total stockholders’ equity	10,674,760	10,354,307
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 12,426,311	$ 11,920,276

XML 14 R4.htm IDEA: XBRL DOCUMENT

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 23,695	$ 14,017
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, shares issued (in shares)	4,594,319	4,594,319
Common stock, shares outstanding (in shares)	4,594,319	4,594,319

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Dividend Paid [Member] Retained Earnings [Member]	Dividend Paid [Member]	Dividend Declared [Member] Retained Earnings [Member]	Dividend Declared [Member]	Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019					4,594,319
Balance at Dec. 31, 2019					$ 459,432	$ 10,173,466	$ 10,632,898
Net income						790,307	790,307
Balance (in shares) at Mar. 31, 2020					4,594,319
Balance at Mar. 31, 2020					$ 459,432	10,963,773	11,423,205
Balance (in shares) at Dec. 31, 2019					4,594,319
Balance at Dec. 31, 2019					$ 459,432	10,173,466	10,632,898
Net income							1,976,918
Dividends				$ (645)
Balance (in shares) at Jun. 30, 2020					4,594,319
Balance at Jun. 30, 2020					$ 459,432	10,220,770	10,680,202
Balance (in shares) at Mar. 31, 2020					4,594,319
Balance at Mar. 31, 2020					$ 459,432	10,963,773	11,423,205
Net income						1,186,611	1,186,611
Dividends	$ (1,928,969)	$ (1,928,969)	$ (645)	(645)
Balance (in shares) at Jun. 30, 2020					4,594,319
Balance at Jun. 30, 2020					$ 459,432	10,220,770	10,680,202
Balance (in shares) at Dec. 31, 2020					4,594,319
Balance at Dec. 31, 2020					$ 459,432	9,894,875	10,354,307
Net income						1,181,202	1,181,202
Balance (in shares) at Mar. 31, 2021					4,594,319
Balance at Mar. 31, 2021					$ 459,432	11,076,077	11,535,509
Balance (in shares) at Dec. 31, 2020					4,594,319
Balance at Dec. 31, 2020					$ 459,432	9,894,875	10,354,307
Net income							2,525,726
Dividends				(657)
Balance (in shares) at Jun. 30, 2021					4,594,319
Balance at Jun. 30, 2021					$ 459,432	10,215,328	10,674,760
Balance (in shares) at Mar. 31, 2021					4,594,319
Balance at Mar. 31, 2021					$ 459,432	11,076,077	11,535,509
Net income						1,344,524	1,344,524
Dividends	$ (2,204,616)	$ (2,204,616)	$ (657)	$ (657)
Balance (in shares) at Jun. 30, 2021					4,594,319
Balance at Jun. 30, 2021					$ 459,432	$ 10,215,328	$ 10,674,760

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Dividend Paid [Member]
Dividends declared per share (in dollars per share)	$ 0.48	$ 0.42
Dividend Declared [Member]
Dividends declared per share (in dollars per share)	$ 0.48	$ 0.42

XML 17 R7.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income	$ 2,525,726	$ 1,976,918
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	70,025	81,094
Net gain on marketable securities	(65,527)	(30,584)
Allowance for doubtful accounts	9,678	(992)
Deferred income taxes	149,454	(262,009)
(Increase) decrease in operating assets:
Accounts receivable	(586,995)	927,588
Inventories	497,487	(306,115)
Prepaid expenses and other current assets	(33,751)	(49,044)
Prepaid income taxes	15,740	165,300
(Decrease) increase in operating liabilities:
Accounts payable	(5,797)	24,108
Accrued expenses	41,268	340,486
Income taxes payable		(317,346)
Dividends payable		(617)
Net cash provided by operating activities	2,617,308	3,183,479
Cash flows from investing activities:
Acquisition of property, plant and equipment	(38,758)	(2,996)
Proceeds from sale of marketable securities	1,832,827	3,524,156
Purchase of marketable securities	(2,053,744)	(3,616,962)
Net cash used in investing activities	(259,675)	(95,802)
Cash flows from financing activities:
Dividends paid	(2,204,616)	(1,928,969)
Net cash used in financing activities	(2,204,616)	(1,928,969)
Net increase in cash and cash equivalents	153,017	1,158,708
Cash and cash equivalents at beginning of period	591,444	1,048,311
Cash and cash equivalents at end of period	744,461	2,207,019
Supplemental disclosure of cash flow information
Taxes paid	300,000	300,000
Dividend Declared [Member]
Supplemental disclosure of cash flow information
Supplemental disclosure of non-cash dividends payable	$ 657	$ 645

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Business

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.	Nature of Business

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Basis of Accounting [Text Block]

2.	Basis of Presentation

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Impact of Coronavirus (COVID-19)

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Impact of Coronavirus (COVID-19) [Text Block]

3.	Impact of Coronavirus (COVID-19)

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Use of Estimates

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Use of Estimates Disclosure [Text Block]

4.	Use of Estimates

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Cash and cash Equivalents

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Cash and Cash Equivalents Disclosure [Text Block]

5.	Cash and Cash Equivalents

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

6.	Revenue Recognition

Disaggregated sales by product class are as follows:

	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Cosmetic ingredients	$	1,855,776	$	1,105,919	$	3,486,372	$	2,808,779
Pharmaceuticals		1,149,179		1,192,441		2,292,487		2,231,152
Medical products		620,748		627,450		1,236,774		1,166,646
Industrial products		32,275		28,834		73,213		70,981
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

Disaggregated sales by geographic region are as follows:

	Three months ended				Six months ended
	June 30,				June 30,
	2021		2020		2021		2020
United States*	$	2,773,242	$	2,276,962	$	5,444,629	$	5,068,642
Other countries		884,736		677,682		1,644,217		1,208,916
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

7.	Marketable Securities

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2021			2020			2021			2020
Net gains recognized during the period on marketable securities	$	137,574		$	387,179		$	65,527		$	30,584
Less: Net gains recognized during the period on marketable securities sold during the period		(112,180	)		(4,856	)		(112,180	)		(4,856	)
Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date	$	25,394		$	382,323		$	(46,653	)	$	25,728

• Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following tables summarize the Company’s investments:

June 30, 2021 (unaudited)

	Cost		Fair value		Unrealized gain
Equity Securities
Fixed income mutual funds	$	7,211,831	$	7,356,110	$	144,279
Equity and other mutual funds		408,417		521,715		113,298
Total equity securities		7,620,248		7,877,825		257,577
Total marketable securities	$	7,620,248	$	7,877,825	$	257,577

December 31, 2020 (audited)

Equity Securities
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Inventory Disclosure [Text Block]

8.	Inventories

	June 30,		December 31,
	2021		2020
	(unaudited)		(audited)
Inventories consist of the following:
Raw materials	$	408,594	$	415,415
Work in process		114,105		59,258
Finished products		395,587		941,100
Total inventories	$	918,286	$	1,415,773

As of the date of this report, the Covid-19 pandemic has not materially affected the valuation of the Company’s finished products, work in process, or raw material inventories.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Income Tax Disclosure [Text Block]

9.	Income Taxes

	Three months ended June 30,					Six months ended June 30,
	2021		2020			2021		2020
Provision for federal income taxes - current	$	266,780	$	490,893		$	515,640	$	782,496
Provision for state income taxes - current		---		---			100		150
Provision (benefit) for federal income taxes - deferred		87,461		(177,997	)		149,454		(262,009	)
Total provision for Income taxes	$	354,241	$	312,896		$	665,194	$	520,637

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Defined Contribution Plan

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Retirement Benefits [Text Block]

10.

Defined Contribution Plan

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Other Information

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Other Liabilities Disclosure [Text Block]

11.

Other Information

	June 30, 2021		December 31, 2020
Accrued Expenses	(unaudited)		(audited)
Bonuses	$	126,000	$	210,000
Distribution fees		340,655		325,792
Payroll and related expenses		272,597		245,521
Reserve for outdated material		299,710		302,713
Deferred revenue		190,164		---
Company 401(k) contribution		65,000		---
Audit fee		35,250		50,500
Annual report expenses		31,497		63,432
Sales rebates		24,213		149,346
Other		19,639		16,153
Total accrued expenses	$	1,404,725	$	1,363,457

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Recent Accounting Pronouncements

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Accounting Standards Update and Change in Accounting Principle [Text Block]

12.

Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations of Credit Risk

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

13.

Concentrations of Credit Risk

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 14 - Earnings Per Share

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Earnings Per Share [Text Block]

14.

Earnings Per Share

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 15 - Subsequent Events

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Subsequent Events [Text Block]

15.

Subsequent Events

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Cosmetic ingredients	$	1,855,776	$	1,105,919	$	3,486,372	$	2,808,779
Pharmaceuticals		1,149,179		1,192,441		2,292,487		2,231,152
Medical products		620,748		627,450		1,236,774		1,166,646
Industrial products		32,275		28,834		73,213		70,981
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three months ended				Six months ended
	June 30,				June 30,
	2021		2020		2021		2020
United States*	$	2,773,242	$	2,276,962	$	5,444,629	$	5,068,642
Other countries		884,736		677,682		1,644,217		1,208,916
Total Sales	$	3,657,978	$	2,954,644	$	7,088,846	$	6,277,558

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Gain (Loss) on Securities [Table Text Block]

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2021			2020			2021			2020
Net gains recognized during the period on marketable securities	$	137,574		$	387,179		$	65,527		$	30,584
Less: Net gains recognized during the period on marketable securities sold during the period		(112,180	)		(4,856	)		(112,180	)		(4,856	)
Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date	$	25,394		$	382,323		$	(46,653	)	$	25,728

Marketable Securities [Table Text Block]

	Cost		Fair value		Unrealized gain
Equity Securities
Fixed income mutual funds	$	7,211,831	$	7,356,110	$	144,279
Equity and other mutual funds		408,417		521,715		113,298
Total equity securities		7,620,248		7,877,825		257,577
Total marketable securities	$	7,620,248	$	7,877,825	$	257,577

Equity Securities
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30,		December 31,
	2021		2020
	(unaudited)		(audited)
Inventories consist of the following:
Raw materials	$	408,594	$	415,415
Work in process		114,105		59,258
Finished products		395,587		941,100
Total inventories	$	918,286	$	1,415,773

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Three months ended June 30,					Six months ended June 30,
	2021		2020			2021		2020
Provision for federal income taxes - current	$	266,780	$	490,893		$	515,640	$	782,496
Provision for state income taxes - current		---		---			100		150
Provision (benefit) for federal income taxes - deferred		87,461		(177,997	)		149,454		(262,009	)
Total provision for Income taxes	$	354,241	$	312,896		$	665,194	$	520,637

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 11 - Other Information (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	June 30, 2021		December 31, 2020
Accrued Expenses	(unaudited)		(audited)
Bonuses	$	126,000	$	210,000
Distribution fees		340,655		325,792
Payroll and related expenses		272,597		245,521
Reserve for outdated material		299,710		302,713
Deferred revenue		190,164		---
Company 401(k) contribution		65,000		---
Audit fee		35,250		50,500
Annual report expenses		31,497		63,432
Sales rebates		24,213		149,346
Other		19,639		16,153
Total accrued expenses	$	1,404,725	$	1,363,457

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 5 - Cash and cash Equivalents (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Cash, Uninsured Amount	$ 587,000	$ 653,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 23,695		$ 23,695		$ 14,017
Cosmetic Ingredients [Member] \| Non-US [Member] \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage	24.00%	23.00%	23.00%	19.00%
ASI [Member] \| Non-US [Member] \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage	72.00%	72.00%	69.00%	69.00%
ASI [Member] \| CHINA \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage	43.00%	42.00%	40.00%	34.00%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition - Disaggregated Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net Sales	$ 3,657,978	$ 2,954,644	$ 7,088,846	$ 6,277,558
Cosmetic Ingredients [Member]
Net Sales	1,855,776	1,105,919	3,486,372	2,808,779
Pharmaceuticals [Member]
Net Sales	1,149,179	1,192,441	2,292,487	2,231,152
Medical Product [Member]
Net Sales	620,748	627,450	1,236,774	1,166,646
Industrial And Other [Member]
Net Sales	$ 32,275	$ 28,834	$ 73,213	$ 70,981

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Net Sales

$ 3,657,978

$ 2,954,644

$ 7,088,846

$ 6,277,558

UNITED STATES

Net Sales

^[1]

2,773,242

2,276,962

5,444,629

5,068,642

Non-US [Member]

Net Sales

$ 884,736

$ 677,682

$ 1,644,217

$ 1,208,916

[1]

Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 72% of its sales of the Company’s products in the second quarter of both 2021 and 2020 were to foreign customers, with China representing approximately 43% of those foreign sales in the second quarter of 2021, compared with approximately 42% in the second quarter of 2020.

- Definition

+ References

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Proceeds from Sale and Maturity of Marketable Securities, Total			$ 1,832,827	$ 3,524,156
Debt and Equity Securities, Realized Gain (Loss), Total	$ 112,180	$ 4,856	$ 112,180	$ 4,856

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net gains recognized during the period on marketable securities	$ 137,574	$ 387,179	$ 65,527	$ 30,584
Less: Net gains recognized during the period on marketable securities sold during the period	(112,180)	(4,856)	(112,180)	(4,856)
Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date	$ 25,394	$ 382,323	$ (46,653)	$ 25,728

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities - Summary of Investments (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Equity securities, cost	$ 7,620,248	$ 7,287,151
Equity securities	7,877,825	7,591,381
Equity securities, unrealized gain	257,577	304,230
Marketable securities, cost	7,620,248	7,287,151
Marketable securities	7,877,825	7,591,381
Marketable securities, unrealized gain	257,577	304,230
Fixed Income Securities [Member]
Equity securities, cost	7,211,831	6,703,107
Equity securities	7,356,110	6,907,270
Equity securities, unrealized gain	144,279	204,163
Equity And Other Mutual Funds [Member]
Equity securities, cost	408,417	584,044
Equity securities	521,715	684,111
Equity securities, unrealized gain	$ 113,298	$ 100,067

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Inventory Valuation Reserves, Ending Balance	$ 35,000	$ 35,000
Accrued Reserve for Outdated Material	$ 299,710	$ 302,713

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories - Summary of Inventories (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Raw materials	$ 408,594	$ 415,415
Work in process	114,105	59,258
Finished products	395,587	941,100
Total inventories	$ 918,286	$ 1,415,773

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Provision for federal income taxes - current	$ 266,780	$ 490,893	$ 515,640	$ 782,496
Provision for state income taxes - current			100	150
Provision (benefit) for federal income taxes - deferred	87,461	(177,997)	149,454	(262,009)
Total provision for Income taxes	$ 354,241	$ 312,896	$ 665,194	$ 520,637

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 10 - Defined Contribution Plan (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Defined Contribution Plan, Cost	$ 65,000	$ 72,500
DC Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	1 year
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0
DC Plan [Member] \| Discretionary Contributions Vesting at Two Years [Member]
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	2 years
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%
DC Plan [Member] \| Discretionary Contributions Vesting Each Additional Year [Member]
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	6 years
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 11 - Other Information - Summary of Accrued Expenses (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Bonuses	$ 126,000	$ 210,000
Distribution fees	340,655	325,792
Payroll and related expenses	272,597	245,521
Accrued Reserve for Outdated Material	299,710	302,713
Deferred revenue	190,164
Company 401(k) contribution	65,000
Audit fee	35,250	50,500
Annual report expenses	31,497	63,432
Sales rebates	24,213	149,346
Other	19,639	16,153
Total accrued expenses	$ 1,404,725	$ 1,363,457

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations of Credit Risk (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Marketing Partner [Member]
Number of Customers	1		1
Distributor [Member]
Number of Customers	3	3	3
Distributors and Marketing Partners [Member]
Number of Customers				3
Distributors and Marketing Partners [Member] \| Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Concentration Risk, Percentage	75.00%	76.00%	76.00%	79.00%
Distributors and Marketing Partners [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk, Percentage	73.00%	64.00%	73.00%	64.00%

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note 14 - Earnings Per Share (Details Textual) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share, Basic and Diluted, Total (in dollars per share)	$ 0.29	$ 0.26	$ 0.55	$ 0.43

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 97 222 1 true 25 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://u-g.com/20210630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Statements of Income (Unaudited) Sheet http://u-g.com/20210630/role/statement-statements-of-income-unaudited Statements of Income (Unaudited) Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Current Period Unaudited) Sheet http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited Balance Sheets (Current Period Unaudited) Statements 3 false false R4.htm 003 - Statement - Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 4 false false R5.htm 004 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Nature of Business Sheet http://u-g.com/20210630/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Basis of Presentation Sheet http://u-g.com/20210630/role/statement-note-2-basis-of-presentation Note 2 - Basis of Presentation Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Impact of Coronavirus (COVID-19) Sheet http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19 Note 3 - Impact of Coronavirus (COVID-19) Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Use of Estimates Sheet http://u-g.com/20210630/role/statement-note-4-use-of-estimates- Note 4 - Use of Estimates Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Cash and cash Equivalents Sheet http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents- Note 5 - Cash and cash Equivalents Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Revenue Recognition Sheet http://u-g.com/20210630/role/statement-note-6-revenue-recognition- Note 6 - Revenue Recognition Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Marketable Securities Sheet http://u-g.com/20210630/role/statement-note-7-marketable-securities Note 7 - Marketable Securities Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Inventories Sheet http://u-g.com/20210630/role/statement-note-8-inventories Note 8 - Inventories Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Income Taxes Sheet http://u-g.com/20210630/role/statement-note-9-income-taxes Note 9 - Income Taxes Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Defined Contribution Plan Sheet http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan Note 10 - Defined Contribution Plan Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Other Information Sheet http://u-g.com/20210630/role/statement-note-11-other-information Note 11 - Other Information Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Recent Accounting Pronouncements Sheet http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements Note 12 - Recent Accounting Pronouncements Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Concentrations of Credit Risk Sheet http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk Note 13 - Concentrations of Credit Risk Notes 20 false false R21.htm 020 - Disclosure - Note 14 - Earnings Per Share Sheet http://u-g.com/20210630/role/statement-note-14-earnings-per-share Note 14 - Earnings Per Share Notes 21 false false R22.htm 021 - Disclosure - Note 15 - Subsequent Events Sheet http://u-g.com/20210630/role/statement-note-15-subsequent-events- Note 15 - Subsequent Events Notes 22 false false R23.htm 022 - Disclosure - Note 6 - Revenue Recognition (Tables) Sheet http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables Note 6 - Revenue Recognition (Tables) Tables http://u-g.com/20210630/role/statement-note-6-revenue-recognition- 23 false false R24.htm 023 - Disclosure - Note 7 - Marketable Securities (Tables) Sheet http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables Note 7 - Marketable Securities (Tables) Tables http://u-g.com/20210630/role/statement-note-7-marketable-securities 24 false false R25.htm 024 - Disclosure - Note 8 - Inventories (Tables) Sheet http://u-g.com/20210630/role/statement-note-8-inventories-tables Note 8 - Inventories (Tables) Tables http://u-g.com/20210630/role/statement-note-8-inventories 25 false false R26.htm 025 - Disclosure - Note 9 - Income Taxes (Tables) Sheet http://u-g.com/20210630/role/statement-note-9-income-taxes-tables Note 9 - Income Taxes (Tables) Tables http://u-g.com/20210630/role/statement-note-9-income-taxes 26 false false R27.htm 026 - Disclosure - Note 11 - Other Information (Tables) Sheet http://u-g.com/20210630/role/statement-note-11-other-information-tables Note 11 - Other Information (Tables) Tables http://u-g.com/20210630/role/statement-note-11-other-information 27 false false R28.htm 027 - Disclosure - Note 5 - Cash and cash Equivalents (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual Note 5 - Cash and cash Equivalents (Details Textual) Details http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents- 28 false false R29.htm 028 - Disclosure - Note 6 - Revenue Recognition (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual Note 6 - Revenue Recognition (Details Textual) Details http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables 29 false false R30.htm 029 - Disclosure - Note 6 - Revenue Recognition - Disaggregated Revenue (Details) Sheet http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details Note 6 - Revenue Recognition - Disaggregated Revenue (Details) Details 30 false false R31.htm 030 - Disclosure - Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) Sheet http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) Details 31 false false R32.htm 031 - Disclosure - Note 7 - Marketable Securities (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual Note 7 - Marketable Securities (Details Textual) Details http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables 32 false false R33.htm 032 - Disclosure - Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Sheet http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Details 33 false false R34.htm 033 - Disclosure - Note 7 - Marketable Securities - Summary of Investments (Details) Sheet http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details Note 7 - Marketable Securities - Summary of Investments (Details) Details 34 false false R35.htm 034 - Disclosure - Note 8 - Inventories (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-8-inventories-details-textual Note 8 - Inventories (Details Textual) Details http://u-g.com/20210630/role/statement-note-8-inventories-tables 35 false false R36.htm 035 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details) Sheet http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details Note 8 - Inventories - Summary of Inventories (Details) Details 36 false false R37.htm 036 - Disclosure - Note 9 - Income Taxes (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual Note 9 - Income Taxes (Details Textual) Details http://u-g.com/20210630/role/statement-note-9-income-taxes-tables 37 false false R38.htm 037 - Disclosure - Note 9 - Income Taxes - Provision for Income Taxes (Details) Sheet http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details Note 9 - Income Taxes - Provision for Income Taxes (Details) Details 38 false false R39.htm 038 - Disclosure - Note 10 - Defined Contribution Plan (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual Note 10 - Defined Contribution Plan (Details Textual) Details http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan 39 false false R40.htm 039 - Disclosure - Note 11 - Other Information - Summary of Accrued Expenses (Details) Sheet http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details Note 11 - Other Information - Summary of Accrued Expenses (Details) Details 40 false false R41.htm 040 - Disclosure - Note 13 - Concentrations of Credit Risk (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual Note 13 - Concentrations of Credit Risk (Details Textual) Details http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk 41 false false R42.htm 041 - Disclosure - Note 14 - Earnings Per Share (Details Textual) Sheet http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual Note 14 - Earnings Per Share (Details Textual) Details http://u-g.com/20210630/role/statement-note-14-earnings-per-share 42 false false All Reports Book All Reports ug20210630_10q.htm ex_272617.htm ex_272618.htm ex_272619.htm ug-20210630.xsd ug-20210630_cal.xml ug-20210630_def.xml ug-20210630_lab.xml ug-20210630_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/country/2021 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ug20210630_10q.htm": { "axisCustom": 0, "axisStandard": 10, "contextCount": 97, "dts": { "calculationLink": { "local": [ "ug-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ug-20210630_def.xml" ] }, "inline": { "local": [ "ug20210630_10q.htm" ] }, "labelLink": { "local": [ "ug-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "ug-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "ug-20210630.xsd" ], "remote": [ "https://xbrl.sec.gov/country/2021/country-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 238, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 22, "http://u-g.com/20210630": 9, "http://xbrl.sec.gov/dei/2021": 6, "total": 37 }, "keyCustom": 12, "keyStandard": 210, "memberCustom": 12, "memberStandard": 13, "nsprefix": "ug", "nsuri": "http://u-g.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://u-g.com/20210630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ug:ImpactOfCoronavirusCovid19TextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 3 - Impact of Coronavirus (COVID-19)", "role": "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "shortName": "Note 3 - Impact of Coronavirus (COVID-19)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ug:ImpactOfCoronavirusCovid19TextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ug:UseOfEstimatesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 4 - Use of Estimates", "role": "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "shortName": "Note 4 - Use of Estimates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ug:UseOfEstimatesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 5 - Cash and cash Equivalents", "role": "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "shortName": "Note 5 - Cash and cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 6 - Revenue Recognition", "role": "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "shortName": "Note 6 - Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 7 - Marketable Securities", "role": "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "shortName": "Note 7 - Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 8 - Inventories", "role": "http://u-g.com/20210630/role/statement-note-8-inventories", "shortName": "Note 8 - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 9 - Income Taxes", "role": "http://u-g.com/20210630/role/statement-note-9-income-taxes", "shortName": "Note 9 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 10 - Defined Contribution Plan", "role": "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "shortName": "Note 10 - Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 11 - Other Information", "role": "http://u-g.com/20210630/role/statement-note-11-other-information", "shortName": "Note 11 - Other Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 12 - Recent Accounting Pronouncements", "role": "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "shortName": "Note 12 - Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Statements of Income (Unaudited)", "role": "http://u-g.com/20210630/role/statement-statements-of-income-unaudited", "shortName": "Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 13 - Concentrations of Credit Risk", "role": "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "shortName": "Note 13 - Concentrations of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 14 - Earnings Per Share", "role": "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "shortName": "Note 14 - Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 15 - Subsequent Events", "role": "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "shortName": "Note 15 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 6 - Revenue Recognition (Tables)", "role": "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "shortName": "Note 6 - Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 7 - Marketable Securities (Tables)", "role": "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "shortName": "Note 7 - Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 8 - Inventories (Tables)", "role": "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "shortName": "Note 8 - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 9 - Income Taxes (Tables)", "role": "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables", "shortName": "Note 9 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 11 - Other Information (Tables)", "role": "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "shortName": "Note 11 - Other Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 5 - Cash and cash Equivalents (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual", "shortName": "Note 5 - Cash and cash Equivalents (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 6 - Revenue Recognition (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "shortName": "Note 6 - Revenue Recognition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Current Period Unaudited)", "role": "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "shortName": "Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 6 - Revenue Recognition - Disaggregated Revenue (Details)", "role": "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "shortName": "Note 6 - Revenue Recognition - Disaggregated Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30_ProductOrServiceAxis-CosmeticIngredientsMember", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 6 - Revenue Recognition - Revenue by Geographic Region (Details)", "role": "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "shortName": "Note 6 - Revenue Recognition - Revenue by Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30_StatementGeographicalAxis-US", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 7 - Marketable Securities (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "shortName": "Note 7 - Marketable Securities (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "role": "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "shortName": "Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 7 - Marketable Securities - Summary of Investments (Details)", "role": "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details", "shortName": "Note 7 - Marketable Securities - Summary of Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 8 - Inventories (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual", "shortName": "Note 8 - Inventories (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details)", "role": "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details", "shortName": "Note 8 - Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 9 - Income Taxes (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual", "shortName": "Note 9 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 9 - Income Taxes - Provision for Income Taxes (Details)", "role": "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "shortName": "Note 9 - Income Taxes - Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 10 - Defined Contribution Plan (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual", "shortName": "Note 10 - Defined Contribution Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 11 - Other Information - Summary of Accrued Expenses (Details)", "role": "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "shortName": "Note 11 - Other Information - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DistributorsAndMarketingPartnersMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 13 - Concentrations of Credit Risk (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "shortName": "Note 13 - Concentrations of Credit Risk (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DistributorsAndMarketingPartnersMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-04-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasicAndDiluted", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 14 - Earnings Per Share (Details Textual)", "role": "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "shortName": "Note 14 - Earnings Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statements of Changes in Stockholders' Equity (Unaudited)", "role": "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "shortName": "Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember", "decimals": "INF", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "role": "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "shortName": "Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Statements of Cash Flows (Unaudited)", "role": "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "shortName": "Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 1 - Nature of Business", "role": "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "shortName": "Note 1 - Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 2 - Basis of Presentation", "role": "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "shortName": "Note 2 - Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20210630_10q.htm", "contextRef": "d_2021-01-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-document-and-entity-information", "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual", "http://u-g.com/20210630/role/statement-note-11-other-information", "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "http://u-g.com/20210630/role/statement-note-8-inventories", "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual", "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details", "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "http://u-g.com/20210630/role/statement-note-9-income-taxes", "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual", "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables", "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-document-and-entity-information", "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual", "http://u-g.com/20210630/role/statement-note-11-other-information", "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "http://u-g.com/20210630/role/statement-note-8-inventories", "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual", "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details", "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "http://u-g.com/20210630/role/statement-note-9-income-taxes", "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual", "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables", "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://u-g.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r128", "r193", "r197", "r402" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r128", "r193", "r197", "r402" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r124", "r193", "r195", "r380", "r399", "r400" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r124", "r193", "r195", "r380", "r399", "r400" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r91", "r95", "r284" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r125", "r126", "r193", "r196", "r401", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r125", "r126", "r193", "r196", "r401", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r91", "r95", "r168", "r284", "r347" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "stringItemType" }, "ug_ASIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding the entity ASI, which is located in Canada.", "label": "ASI [Member]" } } }, "localname": "ASIMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "ug_AccruedAnnualReportExpensesCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value of accrued annual report expenses classified as current liabilities.", "label": "ug_AccruedAnnualReportExpensesCurrent", "terseLabel": "Annual report expenses" } } }, "localname": "AccruedAnnualReportExpensesCurrent", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "ug_AccruedDistributionFeesCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued distribution fees", "label": "ug_AccruedDistributionFeesCurrent", "terseLabel": "Distribution fees" } } }, "localname": "AccruedDistributionFeesCurrent", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "ug_AccruedReserveForOutdatedMaterial": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value on reserves for outdated material.", "label": "ug_AccruedReserveForOutdatedMaterial", "terseLabel": "Accrued Reserve for Outdated Material" } } }, "localname": "AccruedReserveForOutdatedMaterial", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual" ], "xbrltype": "monetaryItemType" }, "ug_CosmeticIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to cosmetic ingredients.", "label": "Cosmetic Ingredients [Member]" } } }, "localname": "CosmeticIngredientsMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "domainItemType" }, "ug_DCPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents DC plan.", "label": "DC Plan [Member]" } } }, "localname": "DCPlanMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "domainItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "totalLabel": "Marketable securities, cost" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "totalLabel": "Marketable securities" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "totalLabel": "Marketable securities, unrealized gain" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the vesting period of discretionary contributions made under the defined contribution plan.", "label": "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod", "terseLabel": "Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)" } } }, "localname": "DefinedContributionDiscretionaryContributionPlanVestingPeriod", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "durationItemType" }, "ug_DiscretionaryContributionsVestingAtTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents discretionary contributions vesting after two years of employment.", "label": "Discretionary Contributions Vesting at Two Years [Member]" } } }, "localname": "DiscretionaryContributionsVestingAtTwoYearsMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "domainItemType" }, "ug_DiscretionaryContributionsVestingEachAdditionalYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents discretionary contributions vesting each additional year of employment.", "label": "Discretionary Contributions Vesting Each Additional Year [Member]" } } }, "localname": "DiscretionaryContributionsVestingEachAdditionalYearMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "domainItemType" }, "ug_DistributorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the distributor.", "label": "Distributor [Member]" } } }, "localname": "DistributorMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "ug_DistributorsAndMarketingPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents distributors and marketing partners of the company.", "label": "Distributors and Marketing Partners [Member]" } } }, "localname": "DistributorsAndMarketingPartnersMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "ug_EquityAndOtherMutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity And Other Mutual Funds Member", "label": "Equity And Other Mutual Funds [Member]" } } }, "localname": "EquityAndOtherMutualFundsMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "ug_EquitySecuritiesFvniAccumulatedUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of unrealized gain (loss) on equity securities.", "label": "Equity securities, unrealized gain" } } }, "localname": "EquitySecuritiesFvniAccumulatedUnrealizedGainLoss", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_ImpactOfCoronavirusCovid19TextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure pertaining to impact of coronavirus (COVID-19).", "label": "Impact of Coronavirus (COVID-19) [Text Block]" } } }, "localname": "ImpactOfCoronavirusCovid19TextBlock", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19" ], "xbrltype": "textBlockItemType" }, "ug_IncreaseDecreaseInDividendsPayable": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in dividends payable.", "label": "ug_IncreaseDecreaseInDividendsPayable", "terseLabel": "Dividends payable" } } }, "localname": "IncreaseDecreaseInDividendsPayable", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "ug_IndustrialAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Industrial And Other [Member]" } } }, "localname": "IndustrialAndOtherMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "domainItemType" }, "ug_MarketingPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the marking partner.", "label": "Marketing Partner [Member]" } } }, "localname": "MarketingPartnerMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "ug_MedicalProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to medical product.", "label": "Medical Product [Member]" } } }, "localname": "MedicalProductMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "domainItemType" }, "ug_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of customers affecting an entity's concentration risk.", "label": "ug_NumberOfCustomers", "terseLabel": "Number of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "integerItemType" }, "ug_PharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pharmaceuticals [Member]" } } }, "localname": "PharmaceuticalsMember", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details" ], "xbrltype": "domainItemType" }, "ug_UseOfEstimatesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for use of estimates.", "label": "Use of Estimates Disclosure [Text Block]" } } }, "localname": "UseOfEstimatesDisclosureTextBlock", "nsuri": "http://u-g.com/20210630", "presentation": [ "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-" ], "xbrltype": "textBlockItemType" }, "ug_statement-statement-note-11-other-information-summary-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Other Information - Summary of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-11-other-information-summary-of-accrued-expenses-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-11-other-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Other Information" } } }, "localname": "statement-statement-note-11-other-information-tables", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-6-revenue-recognition-disaggregated-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Revenue Recognition - Disaggregated Revenue (Details)" } } }, "localname": "statement-statement-note-6-revenue-recognition-disaggregated-revenue-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-6-revenue-recognition-revenue-by-geographic-region-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Revenue Recognition - Revenue by Geographic Region (Details)" } } }, "localname": "statement-statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-6-revenue-recognition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Revenue Recognition" } } }, "localname": "statement-statement-note-6-revenue-recognition-tables", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)" } } }, "localname": "statement-statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-7-marketable-securities-summary-of-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Marketable Securities - Summary of Investments (Details)" } } }, "localname": "statement-statement-note-7-marketable-securities-summary-of-investments-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-7-marketable-securities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Marketable Securities" } } }, "localname": "statement-statement-note-7-marketable-securities-tables", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-8-inventories-summary-of-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Inventories - Summary of Inventories (Details)" } } }, "localname": "statement-statement-note-8-inventories-summary-of-inventories-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-8-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Inventories" } } }, "localname": "statement-statement-note-8-inventories-tables", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-9-income-taxes-provision-for-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Income Taxes - Provision for Income Taxes (Details)" } } }, "localname": "statement-statement-note-9-income-taxes-provision-for-income-taxes-details", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "ug_statement-statement-note-9-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Income Taxes" } } }, "localname": "statement-statement-note-9-income-taxes-tables", "nsuri": "http://u-g.com/20210630", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r23", "r129", "r130" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $23,695 at June 30, 2021 and $14,017 December 31, 2020" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r14", "r15", "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedBonusesCurrent", "terseLabel": "Bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedMarketingCostsCurrent", "terseLabel": "Sales rebates" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Audit fee" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r14", "r15", "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedSalariesCurrent", "terseLabel": "Payroll and related expenses" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r165" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r131", "r146", "r148", "r150" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r131", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r74", "r114", "r117", "r122", "r142", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r319", "r321", "r331", "r343", "r345", "r385", "r392" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r49", "r74", "r142", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r319", "r321", "r331", "r343", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r13", "r164" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r38", "r71" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r66", "r71", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r66", "r335" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r167", "r387", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r79", "r80", "r326" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r182" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock $.10 par value, 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r107", "r108", "r128", "r329", "r330", "r414" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r107", "r108", "r128", "r329", "r330", "r411", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r107", "r108", "r128", "r329", "r330", "r411", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r107", "r108", "r128", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r107", "r108", "r128", "r329", "r330", "r414" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r60", "r380" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r59" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r75", "r301", "r311" ], "calculation": { "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Provision for federal income taxes - current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r75", "r301", "r311" ], "calculation": { "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Provision for state income taxes - current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r105", "r128" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r57", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Net gains recognized during the period on marketable securities" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss", "negatedLabel": "Less: Net gains recognized during the period on marketable securities sold during the period", "terseLabel": "Debt and Equity Securities, Realized Gain (Loss), Total" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.", "label": "Unrealized gains (losses) recognized during the reporting period on marketable securities still held at the reporting date" } } }, "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r75", "r302", "r311" ], "calculation": { "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Provision (benefit) for federal income taxes - deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r69", "r75", "r302", "r311", "r312", "r313" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r294", "r295" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "us-gaap_DeferredRevenueCurrent", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r69", "r112" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-11-other-information", "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "http://u-g.com/20210630/role/statement-note-8-inventories", "http://u-g.com/20210630/role/statement-note-9-income-taxes" ], "xbrltype": "stringItemType" }, "us-gaap_DividendDeclaredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.", "label": "Dividend Declared [Member]" } } }, "localname": "DividendDeclaredMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings to shareholders either in cash, property, or capital stock.", "label": "Dividend Paid [Member]" } } }, "localname": "DividendPaidMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r183", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends", "terseLabel": "Supplemental disclosure of non-cash dividends payable" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r15", "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings per common share (basic and diluted) (in dollars per share)", "terseLabel": "Earnings Per Share, Basic and Diluted, Total (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-14-earnings-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r52", "r53", "r54", "r79", "r80", "r81", "r85", "r92", "r94", "r104", "r143", "r182", "r183", "r287", "r288", "r289", "r304", "r305", "r326", "r336", "r337", "r338", "r339", "r340", "r341", "r403", "r404", "r405", "r439" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r328" ], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity securities, cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r136", "r137", "r139", "r140", "r141", "r147", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r180", "r181", "r324", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r227", "r272" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Factory equipment and fixtures" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r106", "r414" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r114", "r116", "r118", "r121", "r123" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r76", "r297", "r299", "r300", "r309", "r314", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r77", "r93", "r94", "r113", "r296", "r310", "r315", "r398" ], "calculation": { "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "negatedLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase) decrease in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Decrease) increase in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r68" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidTaxes", "negatedLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r30", "r160" ], "calculation": { "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r48", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r32", "r160" ], "calculation": { "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r48", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves, Ending Balance" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r31", "r160" ], "calculation": { "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r138", "r384", "r389", "r412", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r12", "r39" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r74", "r142", "r331", "r345", "r386", "r394" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r74", "r142", "r169", "r170", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r320", "r321", "r322", "r331", "r343", "r344", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r7", "r42" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "us-gaap_MarketableSecuritiesCurrent", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Net gain on marketable securities" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "us-gaap_MarketableSecuritiesRealizedGainLoss", "negatedLabel": "Net gain on marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r66" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r66" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r66", "r67", "r70" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r50", "r51", "r54", "r55", "r70", "r74", "r84", "r88", "r89", "r90", "r91", "r93", "r94", "r98", "r114", "r116", "r118", "r121", "r123", "r142", "r169", "r170", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r327", "r331", "r388", "r397" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "NET INCOME" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r82", "r83", "r86", "r87", "r95", "r96", "r97", "r133", "r134", "r144", "r145", "r198", "r199", "r200", "r201", "r290", "r306", "r307", "r308", "r325", "r332", "r333", "r334", "r342", "r381", "r382", "r383", "r406", "r407", "r408", "r409", "r410", "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r114", "r116", "r118", "r121", "r123" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r3", "r78", "r109", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-1-nature-of-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r43" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r65" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r135" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Acquisition of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r226", "r228", "r234", "r252", "r254", "r255", "r256", "r257", "r258", "r272", "r273", "r274", "r275", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r21", "r203", "r204", "r225", "r272" ], "calculation": { "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "terseLabel": "Company 401(k) contribution" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r36", "r37" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r8", "r10", "r162", "r163" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from sale of marketable securities", "terseLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net property, plant, and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r164" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Total property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r166", "r345", "r390", "r395" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentNet", "totalLabel": "Total property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r56", "r149" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r292", "r379", "r424" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r183", "r291", "r345", "r393", "r406", "r410" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r79", "r80", "r81", "r85", "r92", "r94", "r143", "r287", "r288", "r289", "r304", "r305", "r326", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r256", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r256", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r110", "r111", "r115", "r119", "r120", "r124", "r125", "r128", "r192", "r193", "r380" ], "calculation": { "http://u-g.com/20210630/role/statement-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Net Sales", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r194", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r107", "r128" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueSegmentMember": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Segment Benchmark [Member]" } } }, "localname": "SalesRevenueSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r17", "r33", "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-8-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r47", "r52", "r53", "r54", "r79", "r80", "r81", "r85", "r92", "r94", "r104", "r143", "r182", "r183", "r287", "r288", "r289", "r304", "r305", "r326", "r336", "r337", "r338", "r339", "r340", "r341", "r403", "r404", "r405", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual", "http://u-g.com/20210630/role/statement-note-11-other-information", "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "http://u-g.com/20210630/role/statement-note-8-inventories", "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual", "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details", "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "http://u-g.com/20210630/role/statement-note-9-income-taxes", "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual", "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables", "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r104", "r380" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-note-1-nature-of-business", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan", "http://u-g.com/20210630/role/statement-note-10-defined-contribution-plan-details-textual", "http://u-g.com/20210630/role/statement-note-11-other-information", "http://u-g.com/20210630/role/statement-note-11-other-information-summary-of-accrued-expenses-details", "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "http://u-g.com/20210630/role/statement-note-12-recent-accounting-pronouncements", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk", "http://u-g.com/20210630/role/statement-note-13-concentrations-of-credit-risk-details-textual", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share", "http://u-g.com/20210630/role/statement-note-14-earnings-per-share-details-textual", "http://u-g.com/20210630/role/statement-note-15-subsequent-events-", "http://u-g.com/20210630/role/statement-note-2-basis-of-presentation", "http://u-g.com/20210630/role/statement-note-3-impact-of-coronavirus-covid19", "http://u-g.com/20210630/role/statement-note-4-use-of-estimates-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-", "http://u-g.com/20210630/role/statement-note-5-cash-and-cash-equivalents-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-details-textual", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-disaggregated-revenue-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-revenue-by-geographic-region-details", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "http://u-g.com/20210630/role/statement-note-7-marketable-securities", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-details-textual", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "http://u-g.com/20210630/role/statement-note-8-inventories", "http://u-g.com/20210630/role/statement-note-8-inventories-details-textual", "http://u-g.com/20210630/role/statement-note-8-inventories-summary-of-inventories-details", "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "http://u-g.com/20210630/role/statement-note-9-income-taxes", "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual", "http://u-g.com/20210630/role/statement-note-9-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables", "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r25", "r26", "r74", "r132", "r142", "r331", "r345" ], "calculation": { "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited", "http://u-g.com/20210630/role/statement-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r346", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-15-subsequent-events-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-11-other-information-tables", "http://u-g.com/20210630/role/statement-note-6-revenue-recognition-tables", "http://u-g.com/20210630/role/statement-note-7-marketable-securities-tables", "http://u-g.com/20210630/role/statement-note-8-inventories-tables", "http://u-g.com/20210630/role/statement-note-9-income-taxes-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r136", "r137", "r139", "r140", "r141", "r180", "r181", "r324", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-7-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r293", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-note-9-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average shares (basic and diluted) (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://u-g.com/20210630/role/statement-statements-of-income-unaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r427": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r428": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r429": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r431": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r432": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r433": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r434": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r435": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r436": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r437": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r438": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" } }, "version": "2.1" } ZIP 60 0001171843-21-005820-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-21-005820-xbrl.zip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�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end